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In the cell, cAMP-protein kinase A (PKA) signaling is compartmentalized. Two
different receptor types, both utilizing cAMP and PKA as second messenger and
signal effector, are able to convey separate signals that result in phosphorylation
of distinct substrates. Signal compartmentation is possible primarily because of A
Kinase Anchoring Proteins (AKAPs) that bind both PKA and a target substrate,
effectively co-localizing them. AKAPs are also capable of binding to other
necessary signaling components like adenylate cyclase and phosphodiesterase,
thus enabling AKAPs to coordinate a signaling microdomain containing many of
necessary components. In this thesis I present multiple lines of evidence
demonstrating how AKAP7γ is able to regulate PKA phosphorylation. First, I
show that AKAP7γ is able to self-associate, forming dimers and possibly higher
order oligomers. I predict via computational modeling that this behavior will
increase both the speed and magnitude of PKA signaling. Next, I demonstrate
that AKAP7γ participates in a highly dynamic phosphorylation-state dependent
interaction with phospholamban (PLB), and predict via computational modeling
that this allows low concentrations of AKAP7γ to regulate phosphorylation of
much higher concentrations of substrate. Finally I demonstrate via computational
modeling that contrary to the widely accepted hypothesis of AKAP signaling, the
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catalytic subunit of PKA is likely retained within the AKAP-PKA complex during
signaling events. I further show that the structure of the complex is an important
determinant of substrate phosphorylation. This work offers new insight into the
function of AKAPs and offers an update to the AKAP signaling hypothesis.

	
  

ii

AKAP7γ Regulation of PKA Substrate Phosphorylation
Marc Joseph Rigatti

B.S./B.S., Eastern Connecticut State University, 2007
M.S., University of Connecticut, 2010

A Dissertation
Submitted in Partial Fulfillment of the
Requirements for the Degree of
Doctor of Philosophy
at the
University of Connecticut

2017

	
  

iii

Copyright by
Marc Joseph Rigatti

2017

	
  

iv

APPROVAL PAGE

Doctor of Philosophy Dissertation

AKAP7γ Regulation of PKA Substrate Phosphorylation

Presented by
Marc Rigatti, B.S., M.S.
Major Advisor _____________________________________________________
Kimberly L. Dodge-Kafka
Major Advisor_____________________________________________________
Ion I. Moraru
Associate Advisor _________________________________________________
Ann Cowan
Associate Advisor _________________________________________________
John Carson
Associate Advisor _________________________________________________
Yi Wu

University of Connecticut
2017

	
  

v

Acknowledgements
This work is dedicated to my beautiful wife and daughter. My life has been
forever changed for the better because of you.
First, I would like to acknowledge my PI’s Kim Dodge-Kafka and Ion Moraru. Kim,
thank you for believing in me and for allowing me to pursue work that has been
so far outside of your expertise. Your support and encouragement is greatly
appreciated. Ion, thank you for the many times you have provided me with ideas
or inspiration that have saved my models. You are perhaps the busiest person I
have ever met and at times can be near impossible get a hold of, but somehow
you manage to come through when I absolutely need your help. As a biochemist
with little training in math, I never would have imagined that I would become a
computational biologist, but somehow here I am and I thank you both for
providing me with the opportunity and support.
I would like to thank my committee, Ann Cowan, John Carson, and Yi Wu. Ann
and John, thank you for sticking with me during the entire year I spent pursuing
FCS/PCH. Your help allowed me pull off what I thought at time was nearly
impossible. To all of you, thank you for being so accommodating of my random
unscheduled visits to your office with all of my questions. The accessibility of
CAM faculty is something that makes this department a very special place to be
and has made me feel like I really had the support to pursue so many things that
were outside of my comfort zone.
To the entire Virtual Cell Team: without all of you, my success in computational
modeling would not have been possible. Jim, thank you for the many hours you
have spent with me, discussing all things engineering, physics, chemistry,
programming, biology etc. You have provided me with enough help and guidance
through these past few years that you probably should have been my third co-PI.
To Ed, thank you for all your help re-writing Paul’s software to suit my needs, for
assisting me in learning how to program, and for offering so many helpful
suggestions that have allowed me to hack my way to functional scripts. To Jeff,
thank you for not having a heart attack when I occupy 80% of the cluster space
and generate 4TB of data in a single weekend! To Frank, Dan, and Gerard, thank
you for all of your help. It’s really amazing that I have had such easy access to
you all. I can’t imagine what it would have been like to deal with the occasional
quirks of VCell on my own. Thank you everyone, for being so kind and supportive.
I know I am not officially part of the VCell team, but I feel like I am.
To Ji Yu and Dmo, thank you for providing me with the training and equipment
necessary to pursue single particle tracking of PKA. The project may not have
gone far, but it has provided me with a lot of inspiration for other ideas and
enough data to get them started. Dmo, thank you so much for all of the time you

	
  

vi

have spent training me on the TIRF scope, for the many hours you have spent
analyzing my data, and for all of the thoughtful discussion. Ji, thank you for all the
advice, especially on the analysis of my Langevin dynamic simulations.
To all of my former lab mates, John, Andrew and Arpita: thank you for all of your
hard work in laying the foundations of my work. Our time together in lab was
short, but I’m glad to know you all. Thank you for all of your support and helpful
discussion, and for being available to help me finish some of the work that you
started.
To my family: thank you for all of your support, encouragement, and
unconditional love. Dad, thanks for sharing your love of science, and for never
really growing up. I will always remember the many projects we have built
together; the rockets, CO2 powered cannons, and the neighbors destroyed lawn
chair. Mom, thanks for always being there for me and for sacrificing so much to
allow me to do what I have done. There is no way I would have been able
accomplish half of what I have in life without you. Thank you to both of you for
supporting me on this extremely long journey.
Last but not least, I’d like to thank my wife. I can’t imagine a better person to
share this long journey with. There are few people that could possibly understand
what this is like, but you do. Thank you for all of the discussions of all things
science, for your love and support, and for having such confidence in me.

	
  

vii

Table of Contents
CHAPTER 1	
   INTRODUCTION ........................................................................... 1	
  
CAMP SIGNALING................................................................................................. 2	
  
A-KINASE ANCHORING PROTEINS .......................................................................... 5	
  
AKAP7 (AKAP18)............................................................................................... 9	
  
COORDINATION OF PKA PHOSPHORYLATION BY AKAPS ........................................ 14	
  
CHAPTER 2	
   AKAP7γ OLIGOMERIZATION AUGMENTS PKA SIGNALING . 17	
  
ABSTRACT ......................................................................................................... 18	
  
INTRODUCTION ................................................................................................... 19	
  
MATERIALS AND METHODS .................................................................................. 21	
  
Antibodies ..................................................................................................... 21	
  
Construct design .......................................................................................... 22	
  
Recombinant Protein Purification ................................................................. 22	
  
Cell transfection ............................................................................................ 23	
  
Pull-down Assays ......................................................................................... 24	
  
SPR Analysis ................................................................................................ 25	
  
Peptide array membrane synthesis and S-tagged AKAP7γ overlay............. 25	
  
Photon Counting Histogram Analysis ........................................................... 26	
  
Computational Modeling ............................................................................... 27	
  
RESULTS............................................................................................................ 30	
  
Direct cellular association of AKAP7γ with itself ........................................... 30	
  
Isoform specificity and binding affinity of AKAP7γ oligomers ....................... 32	
  
Dimerization of AKAP7γ can be detected in cells ......................................... 36	
  
Oligomerization of AKAP7γ functions to increase target phosphorylation .... 41	
  
DISCUSSION ....................................................................................................... 43	
  
CHAPTER 3	
   PHOSPHORYLATION-STATE DEPENDENT INTERACTION
BETWEEN AKAP7δ/γ AND PHOSPHOLAMBAN INCREASES
PHOSPHOLAMBAN PHOSPHORYLATION ...................................................... 50	
  
ABSTRACT ......................................................................................................... 51	
  
INTRODUCTION ................................................................................................... 53	
  
EXPERIMENTAL METHODS ................................................................................... 56	
  
Antibodies ..................................................................................................... 56	
  
Expression constructs .................................................................................. 56	
  
Cell Transfection and Immunoprecipitation .................................................. 57	
  
In vitro Phospholamban phosphorylation assays ......................................... 57	
  
Rat neonatal myocyte culture ....................................................................... 58	
  
GST-RII pulldown assay ............................................................................... 59	
  
Computational Modeling of the AKAP7-Phospholamban complex. ............. 59	
  
RESULTS............................................................................................................ 61	
  
AKAP7γ directly binds to phospholamban .................................................... 61	
  
PKA bound to AKAP7δ/γ is responsible for phosphorylation of
phospholamban ............................................................................................ 63	
  
	
  

viii

Described human mutations of phospholamban contained in the AKAP7δ/γ
binding domain decrease complex formation, thereby reducing
phosphorylation ............................................................................................ 65	
  
Phosphorylation of phospholamban decreases the affinity for AKAP7δ/γ
binding .......................................................................................................... 70	
  
Phosphorylation state specific binding of AKAP7δ/γ increases
phospholamban phosphorylation ................................................................. 71	
  
DISCUSSION ....................................................................................................... 76	
  
CHAPTER 4	
   LANGEVIN DYNAMIC SIMULATION OF AKAP-PKA COMPLEX:
RE-ENVISIONING THE LOCAL CONCENTRATION MECHANISM FOR
DIRECTING PKA PHOSPHORYLATION ........................................................... 81	
  
ABSTRACT ......................................................................................................... 82	
  
INTRODUCTION ................................................................................................... 84	
  
METHODS .......................................................................................................... 88	
  
Langevin Dynamic Modeling ........................................................................ 88	
  
Geometry ...................................................................................................... 89	
  
Particle Motion: Diffusion and Constraints Due to Binding ........................... 90	
  
Reactions ..................................................................................................... 91	
  
Data reduction and analysis ......................................................................... 93	
  
Analytical Prediction of Phosphorylation Rate .............................................. 94	
  
RESULTS............................................................................................................ 95	
  
Modeling the AKAP-PKA complex ............................................................... 95	
  
AKAP-PKA complexes with shorter more flexible tethers display faster
characteristic times of enzyme-substrate binding and spend more time in the
bound state on average ................................................................................ 98	
  
Increases in apparent kf of binding and average time spent in the bound
state translate to decreases in characteristic times of phosphorylation ....... 99	
  
Release of the catalytic subunit abrogates the effect of PKA tethering for a
single AKAP-PKA-substrate complex ......................................................... 103	
  
DISCUSSION ..................................................................................................... 106	
  
CHAPTER 5	
   CONCLUSIONS ........................................................................ 113	
  
AKAP7γ Oligomerization augments PKA signaling .................................... 116	
  
Phosphorylation-state dependent interaction between AKAP7δ/γ and
phospholamban increases phospholamban phosphorylation .................... 118	
  
Langevin Dynamic Simulation of AKAP-PKA Complex: Re-envisioning the
local concentration mechanism for directing PKA phosphorylation ............ 120	
  
Concluding Remarks .................................................................................. 122	
  
	
  

	
  

ix

Table of Figures
	
  
Figure 1.1 AKAP compartmentalizes PKA signaling by anchoring PKA to specific
substrates .............................................................................................................. 7	
  
Figure 1.2 AKAP18 isoforms .............................................................................. 11	
  
Figure 2.1 Computational Model of AKAP oligomerization ................................. 29	
  
Figure 2.2 Direct cellular association of AKAP7γ with itself ................................ 31	
  
Figure 2.3 AKAP7γ forms homo-oligomers displaying high affinity interactions. 34	
  
Figure 2.4 Mapping the sites in AKAP7γ responsible for oligomerization ........... 37	
  
Figure 2.5 Photon counting histogram detects dimerization of AKAP7γ in live
cells ..................................................................................................................... 39	
  
Figure 2.6 Oligomerization of AKAP7γ functions to increase target
phosphorylation ................................................................................................... 42	
  
Figure 2.7 Feed-forward model of PKA activation .............................................. 48	
  
Figure 3.1 Direct cellular interaction between AKAP7δ/γ and phospholamban .. 62	
  
Figure 3.2 AKAP7δ/γ anchors PKA to the phospholamban complex to enhance
phosphorylation ................................................................................................... 64	
  
Figure 3.3 Described human mutations of phospholamban disrupt AKAP7γ
binding. ................................................................................................................ 67	
  
Figure 3.4 Phosphorylation of PLB significantly decreases the affinity for
AKAP7δ/γ ............................................................................................................. 69	
  
Figure 3.5 State dependent binding of AKAP to PLB dramatically increases PLB
phosphorylation upon stimulation ........................................................................ 72	
  
Figure 3.6 Increased baseline cAMP reduces dynamic range of PLB
phosphorylation ................................................................................................... 74	
  
Figure 4.1 Langevin Dynamic Model of the AKAP-PKA complex ....................... 96	
  
Figure 4.2 Tether length and flexibility modulate binding of the catalytic subunit
to substrate ........................................................................................................ 100	
  
Figure 4.3 Tether length and flexibility modulate the rate substrate
phosphorylation ................................................................................................. 102	
  
Figure 4.4 Simulation of release of the catalytic subunit from the AKAP-PKA
complex ............................................................................................................. 104	
  

	
  

x

Abbreviations
AMPA – α-amino-3-5-methyl-4-isoxazole propionic acid
AKAP – A Kinase Anchoring Protein
AKAR – A-kinase activity reporter
AC – Adenylate cyclase
C – Catalytic subunit of PKA
cAMP – Cyclic adenine mononucleotide phosphate
Co-IP – Co-immunoprecipitation
CTB – Characteristic time of binding
CTP – Characteristic time of phosphorylation
ENaC – Epithelial Na+ channel
FRET – Forster resonance energy transfer
GFP – Green fluorescence protein
LD – Langevin Dynamics
LTCC – L-type Ca2+ channel
MAP – Mitogen-activated protein
MBP – Maltose binding protein
PCH – Photon counting histogram
PDE – Phosphodiesterase
PKA – cAMP-dependent protein kinase A
PGE1 – Prostaglandin E1
PLB – Phospholamban
PKI – Protein kinase inhibitor
R – Regulatory subunit of PKA
RyR – Ryanodine receptor
SERCA2a – Sarcoplasmic endoplasmic reticular Ca2+ ATPase
SPR – Surface plasmon resonance
TnI – Troponin I
VSNC – Voltage sensitive Na+ channel

	
  

xi

Chapter 1
Introduction
	
  

	
  

1

cAMP Signaling
In 1958, Earl Sutherland and Ted Rall reported the isolation of an unusual
adenine ribonucleotide formed by liver in the presence of ATP, Mg2+, and
epinephrine or glucagon (1). This unusual ribonucleotide that stimulated the
formation of liver phosphorylase in response to epinephrine or glucagon was
called 3,5-AMP, now known as cyclic AMP (cAMP) (2). Since their initial
discovery, the cAMP signaling pathway has become one of the most well
characterized signal transduction systems due to its ubiquitous presence in all
cell

types.

It

is

now

widely

appreciated

that

many

hormones

and

neurotransmitters exert their physiological functions via activation of the cAMP
pathway and its downstream effectors. Hormone binding to seven transmembrane domain G protein-coupled receptors at the cell surface results in the
activation and release of the Gαs subunit. Subsequent activation of adenylate
cyclase (AC) by Gαs stimulates increased production of cAMP and activation of
downstream effectors including cAMP-dependent protein kinase A (PKA), the
guanine nucleotide exchange factor Epac, and cyclic nucleotide-gated ion
channels. Following activation of these downstream effectors, cAMP levels are
returned to baseline via degradation by phosphodiesterases (PDEs).
A decade after the discovery of cAMP, Kuo and Greengard advanced the
idea that ubiquitous cAMP dependent protein kinases mediate most, if not all
effects of cAMP in eukaryotes (3). According to their hypothesis, the ability of a
hormone to produce the appropriate response depends upon expression of the
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appropriate AC-linked receptor and PKA substrates. Thus, receptor expression
determines the sensitivity of a cell type to a particular hormone, and the presence
of specific substrates determines the response. According to Rall, this hypothesis
presented “the unsatisfying picture of the catalytic subunit of protein kinase
swimming about, happily phosphorylating a variety of cellular constituents
whether they need it or not” (4). At the time, activation of AC by hormone binding
at the cell surface was thought to result in uniform increases in cAMP
concentration across the cell due to the high diffusion coefficient of cAMP. Such
increases in cAMP would lead to cell wide activation of PKA and phosphorylation
of all PKA substrates. For cell types that express multiple receptors with separate
downstream targets, this hypothesis did not provide a means for preventing
cross-talk among multiple signaling pathways. Rall’s criticism regarding the
apparent lack of substrate specificity of PKA phosphorylation is even more
pertinent in light of recent evidence demonstrating that a single cell type may
contain over 100 PKA substrates (5).
In the late 1970’s evidence began to accumulate that activation of a single
receptor type did not lead to global substrate phosphorylation, rather it caused
phosphorylation of a specific subset of PKA substrates. The work of Keely
demonstrated that while prostaglandin E1 (PGE1) and epinephrine both produce
increases in cAMP and activation of PKA in the rat heart, only epinephrine
caused a significant increase in glycogen phosphorylase activity (6). Similar work
in adipose tissue by Honeyman and Levy demonstrated that while epinephrine,

	
  

3

isoproterenol,

and

glucagon

produced

parallel

activation

of

glycogen

phosphorylase and lipolysis, serotonin activated glycogen phosphorylase but
failed to induce lipolysis (7). Hayes and Brunton demonstrated further, that
different receptor types are not only capable of producing separate down stream
effects, they also may not share the same pool of cAMP and PKA (8).
Isoproterenol and PGE1 were each found to increase both production of cAMP
and activation of PKA in the rat heart, yet isoproterenol activated glycogen
phosphorylase and induced increased contractility while PGE1 did not.
Importantly, stimulation with both agents had an additive effect on the production
of cAMP and activation of PKA, but did not produce an increase in either
glycogen phosphorylase activity or contractility compared to isoproterenol alone.
These findings formed the basis of the idea of compartmentation, in which it was
hypothesized that each hormone activates a discrete pool of PKA. This
hypothesis is supported by the findings of Corbin et al, who demonstrated that
specific isozymes of PKA are distributed within distinct cellular compartments (9),
thus providing a potential mechanism for compartmentation. By associating with
a specific PKA isozyme, a receptor may target only the substrates associated
with the compartment of the given isozyme. While Hayes and Brunton were
largely correct, the mechanism that enabled anchoring of specific PKA isozymes
to distinct compartments remained unknown. This role is fulfilled by A-Kinase
anchoring proteins (AKAPs).
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A-Kinase Anchoring Proteins
Protein kinase A is a broad specificity serine/threonine kinase consisting
of a regulatory subunit (R) dimer and two catalytic subunits (C). The binding of
two molecules of cAMP to each regulatory subunit induces a conformational shift
that releases the active C subunits (10). Although each of the two subunits
comprising the PKA heterotetramer has several isoforms, their diversity is limited
in comparison to the number of receptors utilizing the cAMP-PKA signaling
pathway. There are four isoforms of the regulatory subunit (RIα, RIβ, RIIα and
RIIβ) and three isoforms of the catalytic subunit (Cα, Cβ, and Cγ), while the total
number of GPCRs in the human genome has recently been estimated at over
800 receptors (11). Several years after the compartmentation hypothesis was
suggested, a previously unknown protein was identified by Sarkar et al as a
contaminant that co-purified with RII following cAMP-sepharose affinity
chromatography (12). This protein, now known as an A-kinase anchoring protein
(AKAP),

provided

the

molecular

mechanism

for

cAMP-PKA

signal

compartmentation (13).
AKAPs are a diverse family of proteins that share little sequence
homology and are defined only by their ability to bind PKA. The total number of
AKAPs is estimated to be >70, resulting from alternative splicing of mRNAs
encoded by 43 different genes (14). While the majority of AKAPs interact only
with RII, a few dual specificity AKAPs have been identified that bind both RI and
RII, though the affinity for RI is typically several fold less (15, 16). AKAPs interact
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with the N-terminal dimerization/docking domain of the R subunit dimer through a
14-18 amino acid amphipathic helix sequence (17). By simultaneously binding to
both PKA and a given substrate, AKAPs direct PKA phosphorylation to a specific
substrate or set of substrates (Fig 1.1).
The functional significance of AKAPs has been well established by
disrupting AKAP-PKA binding (18). Disruption of PKA anchoring by AKAP is
most commonly achieved using Ht31(493-515) peptide, a fragment of an AKAP
cloned from human thyroid. This fragment represents the minimum necessary
region for PKA binding to the AKAP and is generally referred to simply as Ht31
(19). In hippocampal neurons, Ht31 has been shown to uncouple PKA from aamino-3-5-methyl-4-isoxazole propionic acid (AMPA)-type glutamate receptors,
resulting in attenuated postsynaptic AMPA currents (20).

Disruption of PKA

anchoring in the pancreatic β-cell line RINm5F has been demonstrated to block
cAMP responsive insulin secretion and to suppress cAMP mediated intracellular
calcium elevation (21). Similar disruption of normal function by interfering with
PKA anchoring in sperm has been observed as well, with Ht31 inhibiting cAMP
dependent motility in a time and concentration dependent manner (22).
Additionally, it has been demonstrated that disrupting PKA anchoring in rat heart
cells redistributes RII, with loss of the typical striated pattern.

Importantly,

disruption reduces phosphorylation of several key PKA substrates including
phospholamban (PLB), Ryanodine receptor (RyR), and Troponin I (TnI) after
stimulation with isoproterenol, and also produces changes in cardiac contractile
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Figure 1.1 AKAP compartmentalizes PKA signaling by anchoring PKA to specific substrates.
PKA binds to AKAP through its regulatory subunit dimer (R), which associates with AKAP through
the dimerization/docking domain. In the inactive conformation, the catalytic subunit (C) is bound
to the complex via the inhibitory domain of the regulatory subunit. Activation of a GPCR leads to
cAMP production by AC. The increase in cAMP causes local activation and release of the PKA
catalytic subunit resulting in phosphorylation of the AKAP bound substrate, which in this example
+
is a Na channel. The increase in cAMP is confined to the local area and returned to baseline via
PDE. The diffusion of cAMP away from AC and its degradation by PDE is represented by the
yellow gradient.
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parameters (23, 24). Together, these examples clearly show the importance of
PKA anchoring for regulation of substrate phosphorylation, leading to changes in
cellular physiology.
The ability of AKAPs to focus the catalytic activity of PKA on a particular
substrate results from simultaneously associating with both the kinase and
substrate. This has been demonstrated using the uni-molecular Förster
resonance energy transfer (FRET) sensor of PKA activity, A-kinase activity
reporter 2 (AKAR2) (25). By modifying AKAR2 to include a C-terminal RII binding
site, Dodge-Kafka et al were able to show that PKA anchoring to substrate
(AKAR2) augmented both the speed and magnitude of the AKAR2 reporter
response (26). Similar results have been obtained in a more physiologically
relevant context by preventing the association of AKAP with a specific PKA
substrate in cells. β-adrenergic stimulation of cardiac myocytes leads to
phosphorylation of PLB, producing changes in Ca2+ handling and contractility.
Disruption of the AKAP7δ-PLB interaction in rat heart cells using a competitive
peptide inhibitor attenuated isoproterenol induced PLB phosphorylation by up to
50% (27).
Although the primary role of AKAPs is most often considered to be
compartmentation of cAMP-PKA signaling, AKAPs are able to assemble
multimolecular signaling complexes that can include almost any type of
regulatory enzyme (14). The ability of AKAPs to act as scaffolds for enzymes
other than PKA was first discovered in 1995 by Coghlan et al (28). This work
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demonstrated that AKAP79 interacts with and inhibits the actions of protein
phosphatase 2B (PP2B). A ternary complex of PKA, AKAP, and PP2B was
isolated from bovine brain, and colocalization of these components was
established in cultured hippocampal neurites. This result suggests that AKAPs
could coordinate regulation of the phosphorylation state of neuronal substrates.
As the diversity of regulatory enzymes found to interact with AKAPs has
expanded, the idea of cAMP-PKA signal compartmentation has evolved
accordingly. The ability of many AKAPs to form multi-molecular complexes
including AC, PDE, PKA, and a specific PKA substrate allows AKAPs to
coordinate a cAMP microdomain in which all components necessary for signaling
are colocalized (29). Although numerous AKAPs are capable of coordinating
signaling microdomains, the work presented within is focused upon AKAP7
specifically.

AKAP7 (AKAP18)
In 1997 Gray et al reported the discovery of a 15kD protein associated
with the L-type Ca2+ channel (LTCC) that physically links PKA to the channel,
thus facilitating regulation of voltage-dependent potentiation (30). Consistent with
the current AKAP naming scheme, this protein was called AKAP15. Soon after,
an 18kD AKAP was identified that similarly associated with the LTCC (31). While
it was suggested that AKAP18 was likely a homologue of AKAP15, cloning of
AKAP18 related cDNAs revealed that AKAP15 and AKAP18 were, in fact, the
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same (32). Additional isoforms of AKAP18 that arise from the same gene
(AKAP7) but are differentially localized were also discovered. AKAP15/18, now
referred to as AKAP18α, is the shortest of the isoforms and is targeted to lateral
plasma membrane by a C-terminal (residues 1-16) lipid modification region that is
both myristoylated (G1) and palmitoylated (C4, C5) (31). AKAP18β, a slightly
longer AKAP containing a 23 amino acid insertion between the C-terminal lipid
modification region and the RII binding region, localizes to both lateral and apical
plasma membrane. AKAP18γ, a larger 37kD isoform lacking the lipid modification
sites, localizes both to cytosol and to plasma membrane via direct protein-protein
association. AKAP18δ, the largest of the AKAP18 isoforms, is highly similar to
AKAP18γ in both structure and localization with an additional 27 amino acid
segment at the N-terminus (Fig 1.2) (33).
The most well studied isoform of AKAP18 is AKAP18α, which functions
primarily to regulate PKA phosphorylation of various ion channels including the
LTCC (30, 31, 34), the K+ channel complex KvLQT1/Isk (35), and voltagesensitive Na+ channels (VSNC) (36-38). Association of AKAP18α with LTCCs
and VSNCs requires both lipid modification of the N-terminus and direct binding
to the channel through a leucine zipper motif positioned distal to the RII binding
site (amino acids 42-49) (31, 34, 38, 39).

Functionally, AKAP18α has been

demonstrated necessary for PKA dependent modulation of current through all of
the channels mentioned above. Disruption of AKAP18α membrane targeting has
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Figure 1.2 AKAP18 isoforms. A) Structure of each of the isoforms. AKAP18α and AKAP18β
represent the short isoforms, which contain a membrane targeting sequence. The genes for the
short isoforms are identical with the exception of an insertion in AKAP18β (orange region).
AKAP18γ and AKAP18δ represent the long isoforms of AKAP18 and do not contain a membranetargeting region although they do both associate with membranes via protein-protein interaction.
These isoforms are identical except for the first 27 amino acids of AKAP18δ. B) Cellular location
and known substrates of each AKAP18 isoform.
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been shown to reduce Ca2+ current and to blunt GLP-1 mediated insulin secretion
in RINm5F pancreatic β-cells (31). In the heart, AKAP18α anchoring of PKA to
the CaV1.2 channel was found necessary for β-adrenergic regulation of cardiac
contraction with similar reductions in Ca2+ current produced upon disruption of
AKAP18α-Cav1.2 binding (39). Permanent disruption of this interaction in mice,
by knocking out the C-terminal region of the Cav1.2 channel (LTCC), leads to the
development of heart failure (40). The KVLQT1/Isk complex, a component of the
delayed rectifier K+ current that functions to repolarize cardiac myocytes, is also
regulated by AKAP18α. Phosphorylation of KVLQT1 has been shown to increase
current amplitude, increase the characteristic deactivation time of the channel,
and to negatively shift its activation curve (35). In neuronal cells, dopamine
stimulated PKA phosphorylation of NaV1.2 channels reduces peak Na+ current
by 20-50% (41). Disruption of AKAP18a interaction with Nav1.2 channels with a
competitive inhibitory peptide resulted in a 20% reduction in dopamine induced
peak Na+ currents (38).
In comparison to AKAP18α, relatively little is known about the β, δ, and γ
isoforms of AKAP18. Since it’s discovery in 1999 by Trotter et al, nothing has
been published on AKAP18β. The longest isoform of AKAP7, AKAP18δ, was
discovered in 2001 by Klussman and Rosenthal (42). In the kidney, activation of
the vasopressin V2 receptor on the basolateral surface of principal cells in the
collecting duct leads to translocation of aquaporin 2 (AQP2) to the apical
membrane surface, thus facilitating water reabsorption. Translocation of AQP2
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containing vesicles to the apical surface is a PKA dependent process, which
AKAP18δ was demonstrated to regulate (42). Interestingly, while AKAP18δ has
been shown to translocate with AQP2 to the apical surface of principal cells, it
appears that RII dissociates following cAMP stimulation and does not translocate
with AKAP18δ to the apical surface (33). In the mouse heart, AKAP18δ localizes
PKA to the phospholamban (PLB)-sarcoplasmic/endoplasmic reticulum Ca2+
ATPase (SERCA) complex at the sarcoplasmic reticulum (SR) via direct
interaction of AKAP18δ with PLB (27). The interaction of PLB with SERCA
prevents translocation of Ca2+ from the cytosol into the SR (43). Phosphorylation
of PLB at S16 by PKA dissociates PLB from SERCA, thereby restoring its activity.
Disruption of AKAP18δ-PLB binding with Ht31 significantly diminished PLB
phosphorylation,

demonstrating

that

AKAP18δ

is

necessary

for

PLB

phosphorylation (27). It is important to note that AKAP18γ replaces AKAP18δ in
human myocytes, so one may consider AKAP18γ homologous to AKAP18δ in the
regulation of PLB (44). Like AKAP18β, AKAP18γ was identified by Trotter et al in
1999 as a novel long isoform of AKAP18 (32). AKAP18γ was shown to partition
equally between cytosolic and particulate fractions and was hypothesized to
associate with membranes via direct protein-protein interaction due to the lack of
a lipid anchor. While AKAP18γ contains a consensus nuclear localization
sequence, the scaffold is not consistently localized to nuclei. The initial
description of AKAP18γ localization did not note its presence in nuclei, though it
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was later described as localizing RI to the nuclear membrane in mouse
oocytes(45).
Similar to other AKAPs, AKAP18 is capable of binding enzymes other than
PKA, which may serve regulatory functions within the AKAP complex. Coexpression of the epithelial Na+ channel (ENaC) and AKAP18α has been
demonstrated to reduce Na+ conductance by 80-90%, however the reduction in
channel activity was found to be unaffected by either PKA activation or inhibition
(46). Reduced ENaC activity was instead determined to result from the activity of
PKCa, which was shown to interact with AKAP18α. This interaction has been
shown not only for AKAP18α, but also for AKAP18γ (47). Scaffolding of PKCα by
AKAP18 has been demonstrated to increase the activity of PKC, amplifying both
the rate and magnitude of phosphorylation while also insulating PKC from the
effects of inhibitors (48). AKAP18γ has also been shown to interact with protein
phosphatase 1 (PP1) as well as its inhibitor I-1 (49). Phosphorylation of I-1 by
AKAP18γ-linked PKA is known to result in inhibition of PP1 activity and is
suggested to act as a feed-forward mechanism that would potentiate
phosphorylation of AKAP18γ bound PKA substrates like PLB.

Coordination of PKA phosphorylation by AKAPs
The functional and physiological consequences of PKA scaffolding by
AKAPs are well known. This class of proteins not only functions to
compartmentalize signaling by directing PKA phosphorylation to a particular
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substrate, it also augments PKA kinetics, increasing both the rate and magnitude
of phosphorylation (26). However, precisely how AKAPs confer specificity to the
actions of PKA remains unclear. The established mechanism of PKA activation
appears to necessitate the release of the catalytic from its regulatory subunit,
effectively negating the tethering actions of AKAP (10). The most commonly
cited hypothesis is that AKAPs act to increase the local concentration of PKA,
thus upon activation a large pool of active PKA is available to phosphorylate
substrate. This hypothesis is unsatisfying given that the local concentration of
PKA will quickly diminish with the rapid diffusion of PKA away from its point of
release.
Much of the accumulated evidence suggesting that the catalytic subunit
must be released from its regulatory subunit to phosphorylate substrate comes
from in vitro experiments. The possibility that PKA is not released in vivo remains,
and there has been some evidence to suggest that this is the case. In a series of
fluorescence anisotropy experiments with PKA containing a fluorescently labeled
catalytic subunit, Yang et al demonstrated that fluorescence anisotropy did not
increase upon addition of cAMP as was expected, suggesting that the catalytic
subunit was not released (50). They also showed that the un-dissociated
complex retained full catalytic activity. According to Martin et al, the release of the
catalytic subunit is dependent upon auto-phosphorylation of the regulatory
subunit (51). Cell expressing PKA with mutant RII subunits that are unable to be
autophosphorylated do not release the catalytic subunit in response to cAMP
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stimulation. More recently, Smith et al were able to demonstrate that the catalytic
subunit of PKA is retained within the AKAP complex following stimulation of PKA
activity(52).
The work presented here focuses upon the regulation of PKA
phosphorylation by AKAP18γ. In chapter 2, I present evidence of AKAP7γ
dimerization and show via computational modeling how dimerization could
potentially increase the magnitude of substrate phosphorylation. In chapter 3, I
demonstrate that the interaction of AKAP7γ with PLB is dependent on the
phosphorylation state of PLB, and show that this state-dependent interaction may
allow small quantities of AKAP18γ to coordinate phosphorylation of large
quantities of PLB. Finally, in chapter 4, I demonstrate via Langevin Dynamic
simulation of the AKAP-PKA complex that the length and flexibility of the
unstructured tether region of the regulatory subunit potentially modulates the
catalytic rate of PKA. I further demonstrate by modeling that release of the
catalytic subunit from the complex does not result in efficient phosphorylation of
AKAP bound substrate, suggesting that the increased local concentration
hypothesis for compartmentation by AKAPs is incorrect.

Instead, my work

suggests that AKAPs work by affecting the efficiency of phosphorylation
reactions. In sum, the work presented here changes our model of AKAP signaling,
demonstrating a new mechanism of PKA regulation by the AKAP7γ complex.
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AKAP7γ Oligomerization augments PKA signaling
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Abstract

A-kinase anchoring proteins constitute a family of scaffolding proteins that
contribute to spatiotemporal regulation of phosphorylation events mediated by
cAMP-dependent protein kinase A (PKA). In particular, AKAP7 is a family of
alternatively spliced proteins that participates in cardiac calcium dynamics. Here,
we demonstrate via pull-down from transfected HEK-293 cells and by direct
protein-protein association that AKAP7γ self-associates.

Self-association

appears to be an isoform specific phenomenon, as AKAP7α did not associate
with itself or with AKAP7γ. Surface plasmon resonance suggests that the
AKAP7γ self-association occurs via two high affinity binding sites with KD values
in the low nanomolar range. Mapping of the binding sites by peptide array reveals
that AKAP7γ interacts with itself through two regions of the protein. Photon
counting histogram analysis (PCH) of AKAP7γ-EGFP expressed in HEK-293
cells confirmed that AKAP7γ-EGFP self-associates in the cell as well. Lastly,
computational modeling of PKA dynamics within AKAP7γ complexes suggests
that oligomerization may augment phosphorylation of scaffolded PKA substrates.
In conclusion, our study reveals AKAP7γ self-associates to form a homo-dimer
and possibly higher-order oligomers and that this phenomenon could be an
important step in mediating effective substrate phosphorylation in cellular
microdomains.
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Introduction
Phosphorylation of target proteins is a key mechanism utilized by the cell
to induce changes in physiology and function. Numerous kinase-substrate
interactions have been defined, yet the mechanism through which specificity of
these phosphorylation events is achieved is still unclear.

Recent work has

suggested that the subcellular localization of signaling enzymes to discrete
locations in the cell confers spatiotemporal control over phosphorylation events
(53). This is facilitated by scaffolding proteins, which tether the kinase to the
same signaling complex as its substrates, allowing for increased speed and
amplification of phosphorylation events (54). While the physiological significance
of many kinase-binding scaffolds has been investigated, the influence of the
molecular architecture of the complex on cellular processes is presently unclear.
Oligomerization of signaling enzymes is an important mechanism for the
transduction of cellular signals (55, 56). Whether forming a hetero or homo
oligomer, this process often begins at the level of the receptor as a first step in
transducing a signal from outside the cell to the intracellular environment (57).
Oligomer formation is not limited to upstream signaling events. A few recent
studies have demonstrated that scaffolding proteins can oligomerize, influencing
their signaling functions. For example, the yeast scaffold Ste5, which initiates the
mitogen-activated protein (MAP) kinase cascade in the Saccharomyces
cerevisiae pheromone response pathway, dimerizes upon pheromone treatment,
to enhance MAP kinase signaling in the cell (58). Similarly, oligomerization of β-
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arrestin1 sequesters the scaffold in the cytoplasm, inhibiting its nuclear actions
(59). Importantly, these examples demonstrate that oligomerization greatly
impacts the function of the scaffold.
For cAMP signaling, A-kinase anchoring proteins (AKAPs) focus the
actions of the cAMP-dependent protein kinase (PKA) to specific targets, allowing
for microdomains of kinase activity (54). It is becoming evident that AKAPs have
a more profound effect on the regulation of substrate phosphorylation than simply
binding PKA. Many AKAPs have been shown to bind to phosphodiesterases,
protein phosphatases, and adenylyl cyclases as well, allowing for localized
control of cAMP concentration (60-62). Thus, AKAPs are able to coordinate all
components necessary for PKA signaling, lending support to the concept of
holistic substrate phosphorylation regulation by AKAPs.
Our recent investigations focused on defining AKAP7-orchestrated cAMP
microdomains.

AKAP7 is a family of alternatively spliced isoforms that are

known to play a role in cardiac calcium dynamics (27, 63). Here, we reveal that
AKAP7γ oligomerizes, as demonstrated both in vitro and in a cellular context, and
we predict via computational modeling that this may result in enhancement of
PKA substrate phosphorylation. This self-interaction is limited to the large
isoforms of AKAP7, correlating with previous findings that AKAP7α and AKAP7γ
are differentially targeted in the cell and display unique functions (32). Using
peptide array to define the sites on AKAP7γ that mediate binding found several
domains involved in the oligomerization. In agreement with this finding, surface

	
  

20

plasmon resonance analysis confirms that AKAP7γ interacts with itself via
several high-affinity binding sites.

Using photon counting histogram (PCH)

analysis we are able to detect dimerization of AKAP7γ in live cells. In order to
investigate

the

functional

significance

of

oligomerization

on

substrate

phosphorylation, we developed a mathematical model using the Virtual Cell
Software (http://www.vcell.org). Computational analysis suggests that formation
of dimeric complexes enhances the magnitude of substrate phosphorylation.
Collectively, our work demonstrates that oligomerization of AKAP7γ impacts
phosphorylation events orchestrated by the AKAP and suggests that these
findings may be applied to other AKAP complexes.

Materials and Methods
Antibodies
For western blot analyses, the following antibodies were used: mouse
monoclonal anti-GFP (Santa Cruz, 1:1000), goat polyclonal anti-dsRED (Santa
Cruz, 1:1000), rabbit anti-His tag (Millipore, 1:10,000), rabbit anti-mCherry
(BioVision, 1:5000) and mouse anti-GST tag (Santa Cruz, 1:10,000).

To

immunoprecipitate EGFP-tagged proteins, rabbit anti-GFP (Santa Cruz 3 µg) was
used.
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Construct design
AKAP7γ-pET32a, AKAP7α-EGFP-N1 and AKAP7γ-EGFP-N1 were used as
previously described (31, 32, 49). AKAP7γ 1-150-EGFP and AKAP7γ 150-endEGFP were constructed by PCR amplification and sub-cloning into the EcoRIBamHI sites of pEGFP-N1 (Clontech). AKAP7γ-pMAL was constructed by PCR
amplification and sub-cloning into the BamHI-EcoRI sites of pMal-c5E (NEB).
AKAP7γ-mCherry was constructed by PCR amplification and sub-cloning into the
EcoRI-BamHI sites of pmCherry-C1 (Clontech). Monomeric EGFP and tandem
EGFP used for PCH analysis were obtained from the lab of Dr. Kathy HerrickDavis.

Recombinant Protein Purification
For purification of recombinant AKAP7γ-His/S-tag, bacteria were grown to OD595
0.8 then induced with IPTG (1mM final concentration) for 3hrs. After
centrifugation, the bacteria were lysed in binding buffer (20mM HEPES (pH 7.4),
0.5M NaCl, 5mM imidazole along with 0.5% triton-X, 0.25mg/ml lysozyme, 1mM
DTT, 1mM EDTA, and Protease Inhibitor Cocktail) for 2hrs. Following
centrifugation, protein was purified from supernatant by Ni-NTA agarose
pulldown overnight (0.5mL of 50% slurry; Ni-NTA solution, Qiagen). Ni-NTA
agarose was washed 3x in binding buffer and protein was eluted with binding
buffer + 800mM imidizole. Protein was concentrated with Amicon Ultra centrifugal
filters (Millipore). Elution buffer was slowly exchanged with PBS while
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concentrating the protein in the centrifugal tubes. Protein concentration was
determined by comparison to BSA standards via image densitometry of
coomassie stained SDS-PAGE gels. Image densitometry was performed with
Image J software (NIH).
A similar protocol was followed for AKAP7γ-maltose binding protein (MBP)
purification. The MBP tagged protein was lysed in buffer containing protease
inhibitor cocktail (20mM Tris-HCl (pH 7.4), 200mM NaCl, 1mM each of EDTA, Na
Azide, and DTT). Separated cell lysate was passed through amylose resin
packed column, followed by 5 washes with lysis buffer. The protein was eluted
with lysis buffer containing 10mM maltose. The protein was concentrated and
analyzed as described above.

Cell transfection
For analysis of AKAP7γ binding to itself, HEK-293 cells at 50% confluency
were transfected using calcium phosphate precipitation with pEGFP-AKAP7γ and
either mCherry-AKAP7γ or mCherry control (10µg) overnight under 5% CO2 at
37°C. Cells were harvested 18hrs later for cell extract.
For PCH, HEK-293 cells were grown on uncoated glass coverslips to 70%
confluency and transfected with 300ng plasmid DNA (EGFP, tandem EGFP or
AKAP7γ-EGFP) in Opti-MEM (Invitrogen) serum free medium using 6µl PLUS
reagent and 4µl lipofectamine. After 2hrs, transfection media was replaced with
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serum supplemented DMEM (10%FBS). Cells were used for photon counting
histogram analysis 12-24hrs post-transfection.

Pull-down Assays
In-vitro: Purified His/S tagged AKAP7γ (5µg) was incubated with either AKAP7γMBP (5µg) or MBP (5µg), and rocked overnight at 4°C. The next day, the
amylose resin was added for 4hrs to isolate the complex. The amylose beads
were washed 4x in lysis buffer (as described in maltose tagged protein
purification above) for 10-15min while rocking. The components of the complex
were then separated via SDS-PAGE and analyzed by western blot.

From cell supernatant: Lysates prepared from AKAP7γ-EGFP transfected HEK293 cells were incubated with either 5µg purified recombinant AKAP7α-His/S-tag
pre-loaded on S-agarose beads (Novagen), or with purified 5µg AKAP7γ-MBP
pre-loaded on amylose agarose beads (Novagen). For control groups, either
unrelated His/S-tag protein or isolated MBP was used. The pull-downs were
rocked overnight at 4°C, followed by 4 washes with their respective buffers for
10-15min while rocking. The isolated complex was then subjected to separation
via SDS-PAGE followed by western blot analysis.
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SPR Analysis
SPR analysis was performed using the BIAcore T100 platform. Purified
recombinant AKAP7γ or AKAP7α were covalently immobilized to the surface of a
sensor chip (BIAcore type CM5) using NHS (N-hydroxysuccinamide) and EDC
[1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide] (Biacore amine coupling kit).
The amount of ligand bound was 150RU (resonance units). Protein analytes
(AKAP7γ or AKAP7α) were diluted over a range of concentrations (12.5-200nM)
in HBS buffer (10mM Hepes (pH 7.4), 150mM NaCl and 0.005% Surfactant P20)
and were injected over the sensor surface at a flow rate of 30µl/min for 300s.
Post injection phase, dissociation was monitored in HBS buffer for 300s at the
same flow rate. The surface was regenerated between injections using 10mM
NaCl at a flow rate of 50µl/min for 30s. Sensorgrams were analyzed by BIAcore
T100 evaluation software using the appropriate biophysical models.

Peptide array membrane synthesis and S-tagged AKAP7γ overlay
Human AKAP7γ peptides were synthesized as 20-mer peptides with three amino
acid offsets on membranes using a Multipep automated peptide synthesizer
(INTAVIS Bioanalytical Instruments AG, Koeln, Germany). The peptide array
membranes were blocked for 2 hours in 1% casein in TBST (tris-buffered saline
with 1% tween) before incubation with 2 µg/ml recombinant human S-tagged
AKAP7γ in 1% casein (in TBST) overnight at 4°C. Thereafter the membranes
were washed five times in TBST for 5 min before incubation with HRP-conjugated
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anti-S tag antibody (Abcam, ab18589, 1:2500) for 1 hour at room temperature.
Binding was detected using ECL Prime (RPN 2232, GE HealthCare) and
chemiluminescence signals were detected by Las 1000 (Fujifilm, Tokyo, Japan).

Photon Counting Histogram Analysis
Photon counting in live HEK-293 cells was performed with a Zeiss LSM 510
ConFocor3 confocal microscope mounted on an AxioVert 200M. Excitation was
achieved at 488nm with a 30mW Argon laser at 50% power with attenuation set
to 0.5. Fluorescence emission was collected with a 40X 1.2NA water immersion
objective (Zeiss C-Apochromat 1.2W Korr UV-Vis-IR). Detection was performed
with an avalanche photodiode (Zeiss). For each cell, five 10s measurements
were made from five different locations within a given cell. Photon-counting
histograms (PCH) were generated using LSM-FCS software with a bin time of
10µs. Global analysis of measurements with count rates ranging from 20-100
kHz was performed for each construct. Monomeric and dimeric (tandem) EGFP
histograms were fit using a single component model, while AKAP7γ-EGFP
histograms were fit using a two-component model with the brightness values
constrained to those derived from the fit of the monomeric and dimeric EGFP.
Measurements

exhibiting photo-bleaching or other anomalies

producing

instability of the fluctuation trace were excluded from analysis. A single-photon
three-dimensional Gaussian model was assumed for the excitation volume.
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Computational Modeling
A

compartmental

deterministic

model

of

scaffold

oligomerization

was

implemented using the Virtual Cell modeling software (http://www.vcell.org). The
model is composed of 18 species, three compartments (plasma membrane,
cytosol, and endoplasmic reticular membrane), and 11 reactions. The reaction
network can be considered as being composed of four general modules: 1)
production and degradation of cAMP, 2) the dynamic interactions of regulatory
subunit, catalytic subunit and cAMP in the cytosol, 3) the dynamics of these
same proteins and cAMP scaffolded on the ER membrane by AKAP, and 4)
phosphorylation/dephosphorylation of target protein X on the ER membrane. A
diagram of the reaction network and table of the kinetic parameters is shown in
figure 1. For each oligomeric state of the scaffold represented in the different
versions of the model, the concentration of each species is initialized with a value
near steady state in unstimulated conditions. Each simulation is allowed to run for
200s allowing each species to reach its equilibrium constant for each oligomer
before stimulation. Stimulation of PKA activity is achieved by increasing the
amount of AC present on the plasma membrane from 5/µm2 to 50/µm2 for a
period of 100s, simulating the increase in Gs-associated AC during β-adrenergic
stimulation. The resulting increase in cAMP leads to activation of scaffolded PKA
and phosphorylation of the target protein X. Active PKA is then inactivated by
interacting with PKI. The ability of PKA to self-regulate via autophosphorylation
has been shown previously (51). We hypothesized that if a single catalytic
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subunit were to be activated within an AKAP complex, this may subsequently
lead to activation of the remaining population of PKA within the complex. This
hypothesis was implemented via the following equation (eq. 1). This equation
adjusts for the probability of all catalytic subunits within the oligomeric complex
becoming active following activation of a single catalytic subunit in the complex,
where n represents the oligomeric state of the scaffold (ex. 1 = monomer, 2 =
dimer):
(1) 𝑇𝑜𝑡𝑎𝑙  𝐴𝐾𝐴𝑃  𝑏𝑜𝑢𝑛𝑑  𝑃𝐾𝐴

1−

!"#$%&'( !
!"#$%

∗𝑛

The result of eq. 1 represents the amount of catalytic subunit available to
phosphorylate its target, X, and is substituted for [E] in the Henri-Michaelis
Menten irreversible reaction step for phosphorylation of X (eq 2).
(2) 𝑉 =

! ∙!!"# ∙[!]
!! ![!]

Simulations of all oligomeric states have the same amount of active AKAPscaffolded PKA both at equilibrium and during stimulation. The behavior of the
AKAP-scaffolded PKA is altered by eq. 1&2 to reflect the hypothesized behavior
in each oligomeric state.
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Figure 2.1 Computational Model of AKAP oligomerization A) Network diagram B) Reaction
kinetic parameters
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Results
Direct cellular association of AKAP7γ with itself
In order to understand the molecular architecture of the AKAP7γ signaling
complex and to determine if the AKAP can be the basis for higher order
structures, we first looked to see if purified, recombinant AKAP7γ could pulldown
an AKAP7γ complex when transiently expressed in cells. Lysate prepared from
HEK-293 cells transfected with AKAP7γ-EGFP was incubated with amylose
beads charged with either AKAP7γ-maltose binding protein (MBP) or MBP alone.
The protein stain of the nitrocellulose before western blot analysis showing
AKAP7γ-MBP (lanes 1 and 2) or MBP alone (lanes 3 and 4) is shown in Figure
2.2A, lower panel. Input lysate (20µl) from cells expressing AKAP7γ-EGFP is
shown in lane 5. Importantly, AKAP7γ-MBP was able to pulldown AKAP7γ-EGFP
from the transfected cell lysate (Figure 2.2A, upper panel, lanes 1 and 2),
suggesting the AKAP7γ signaling complex may contain multiple AKAP7γ
molecules. As a control, beads charged with purified MBP alone did not pulldown
AKAP7γ-EGFP (Figure 2.2A, upper panel, lanes 3 and 4). To verify the existence
of such complexes in cells, we co-expressed AKAP7γ-mCherry with either
AKAP7γ-EGFP or EGFP alone in HEK-293 cells. AKAP7γ-mCherry input (20 µL)
for

each

immunoprecipitation

is

shown

in

Figure

2.2B,

lower

panel.

Immunoprecipitates from these cells isolated with an anti-GFP antibody
demonstrate that AKAP7γ-mCherry and AKAP7γ-EGFP associate in cells (Figure
2.2B, upper panel, lanes 3 and 4), while EGFP control does not co-precipitate
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Figure 2.2 Direct cellular association of AKAP7γ with itself.
A) Lysates from AKAP7γ-EGFP transfected HEK-293 cells were subjected to pulldown assays
using bacterially purified AKAP7γ-MBP (maltose binding protein) pre-charged on amylose
agarose resin (lanes 1 and 2) or Maltose pre-charged on amylose agarose resin (lanes 3 and 4).
Input from the transfected cells (20µl) is shown in lane 5. Anti-GFP antibody was used for
detecting protein interactions by Western blot analysis (upper panel) while the protein stain of the
nitrocellulose before western blot analysis is shown in the lower panel. n=3. B) Western blot
analysis of anti-GFP immunoprecipitates isolated from HEK-293 cells co-transfected with
AKAP7γ-mCherry and either EGFP alone, or AKAP7γ-EGFP (upper panel). To confirm
immunoprecipitation of both EGFP and AKAP7γ-EGFP, the nitrocellulose membranes were
stripped and reprobed for GFP using a monoclonal anti-GFP antibody (middle panel). Lower
panel depicts mCherry western blot analysis of the input from each condition. n=3. C) In vitro
pulldown of purified S-tagged AKAP7γ incubated with AKAP7γ-MBP precharged on amylose
agarose resin (lanes 1 and 2) or control MBP (lane 3). Anti-His antibody was used to detect the
interaction (upper panel). Equal amounts of S-tagged AKAP7γ were used in each condition, as
shown by analysis of the input used in each experiment (middle panel). Lower panel shows the
protein stain of the nitrocellulose before western blot analysis to demonstrate equal amounts of
MBP-tagged proteins. n=3.
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AKAP7γ-mCherry (lanes 1 and 2). As a control, both the EGFP (lanes 1 and 2)
and AKAP7γ-EGFP (lanes 3 and 4) immunoprecipitates were probed with antiGFP to demonstrate the immunoprecipitation of both proteins (Figure 2.2B,
middle panel). This co-precipitation could be due to multiple binding sites on
other common binding partners within the AKAP complex.

To determine if

AKAP7γ can directly associate with itself, we conducted a pulldown assay using
amylose beads charged with either bacterially expressed AKAP7γ-MBP (lanes 1
and 2) or MBP alone (lane 3) incubated with bacterially expressed S-tagged
AKAP7γ. The protein stain of the nitrocellulose membrane before western blot
analysis displaying the MPB tagged proteins used is shown in Figure 2.2C, lower
panel. S-tagged AKAP7γ input for each experiment is shown in the middle panel.
Importantly, we detect a direct association between S-tagged AKAP7γ and
AKAP7γ-MBP (lanes 1 and 2, upper panel), but not S-tagged AKAP7γ and MBP
(lane 3, upper panel). Based on these experiments, we conclude AKAP7γ can
stably associate with itself.

Isoform specificity and binding affinity of AKAP7γ oligomers
The AKAP7 gene encodes at least 4 alternatively spliced isoforms: α, β, γ,
and δ (32). The smaller isoforms (α & β) are lipid modified in their N-terminal
domain, directing their location to the plasma membrane (31). However, the
larger isoforms (γ & δ) require additional protein-protein interactions for their
intracellular targeting (32). We investigated whether the shorter isoforms could
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also associate with themselves or other isoforms. To address this question,
lysate was prepared from HEK-293 cells transfected with AKAP7γ-EGFP and
incubated with purified recombinant S-tagged AKAP7α or AKAP7γ bound to Sprotein beads. The protein stain of the nitrocellulose before western blot analysis
demonstrating the beads are charged with AKAP7α (lanes 2 and 3) or AKAPγ
(lanes 4 and 5) is shown in Figure 2.3A, lower panel. Input lysate (20 µl) from
cells expressing AKAP7γ-EGFP is shown in lane 1.

Importantly, S-tagged

AKAP7γ was able to pulldown AKAP7γ-EGFP specifically from the transfected
cell lysate (Figure 2.3A, upper panel, lanes 4 and 5). However, we did not detect
the presence of AKAP7γ-EGFP with AKAP7α pulldowns (Figure 2.3A, upper
panel, lanes 2 and 3), suggesting there is no cross isoform interaction. To further
confirm this observation, we conducted the inverse experiment. Lysate collected
from HEK-293 cells transfected with AKAP7α-EGFP was incubated with S-beads
charged with S-tagged AKAP7α (lanes 2 and 3) or AKAP7γ (lanes 4 and 5). As
expected, we did not detect any interaction between the two isoforms (Figure
2.3B, upper panel).
To further increase our understanding of this interaction, the detailed
binding kinetics of the AKAP7γ interaction were analyzed by surface plasmon
resonance (SPR).

AKAP7γ and AKAP7α were chemically conjugated to

separate flow chambers of a CM5 sensor chip. A range of concentrations of
either AKAP7γ (black) or AKAP7α (red) (25nM to 200nM) was injected, and the
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Figure 2.3 AKAP7γ forms homo-oligomers displaying high affinity interactions.
A) Lysates from AKAP7γ-EGFP transfected HEK-293 cells were subjected to pulldown assays
using bacterially purified S-tagged AKAP7α (lanes 2 and 3) or AKAP7γ (lanes 4 and 5)
precharged on S-protein resin. Anti-GFP antibody was used for detecting protein interactions by
western blot analysis (upper panel). Protein stain of the nitrocellulose membrane before western
blot analysis is shown in the lower panel. Input from the transfected cells (20µl) is shown in lane 1.
n=3. B) Lysates from AKAP7α-EGFP transfected HEK-293 cells were subjected to pulldown
assays using bacterially purified S-tagged AKAP7α (lanes 2 and 3) or AKAP7γ (lanes 4 and 5)
precharged on S-protein resin. Anti-GFP antibody was used for detecting protein interactions by
western blot analysis (upper panel). Protein stain of the nitrocellulose membrane before western
blot analysis is shown in the lower panel. Input from the transfected cells (20µl) is shown in lane 1.
n=3. C) SPR was performed by immobilizing 150RU of AKAP7γ (black) and AKAP7α (red) in
separate flow cells on a CM-5 chip and measuring the response when passing over a range of
concentrations (25-200nM) of either AKAP7α (D) or AKAP7γ (C). The sensorgram was best fit
with a heterogeneous ligand model suggesting the presence of two binding sites on AKAP7γ. The
2
affinities of the two binding sites were 0.537nM and 79.7nM (χ = 1.33), as determined by the
BIAcore T100 evaluation software.
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binding dissociation constant (KD) was determined from the fit of the
sensorgrams. We detected a high affinity interaction between AKAP7γ and itself
that is best fit with a heterogeneous ligand model, suggesting at least two sites of
interaction that display binding affinities of 0.537nM and 79.7nM (χ2 = 1.33) (Fig.
2.3C). However, no significant binding between AKAP7α and AKAP7γ was
detected. This was confirmed in reciprocal experiments, where we chemically
conjugated AKAP7α to the sensor. No binding between AKAP7α and AKAP7γ or
itself was detected (Fig. 2.3D). These results support the hypothesis that AKAP7γ
forms only homo-associations.

Mapping the sites in AKAP7γ responsible for homo-association.
The SPR results suggest that multiple sites of interaction may exist
between AKAP7γ and itself. To determine the number and location of binding
sites, a series of AKAP7γ fragments were created (Figure 2.4A) and incubated
with lysate from HEK-293 cells transfected with AKAP7γ-EGFP (Fig 2.4B). The
protein stain of S-protein beads charged with the different AKAP7 proteins used
in the experiment is shown in Figure 2.4A, lower panel. Input lysate (20µl) from
cells expressing AKAP7γ-EGFP is shown in the designated lane. In confirmation
of our previous results, recombinant purified full-length AKAP7γ, but not AKAP7α,
was able to pulldown AKAP7γ-EGFP from transfected cell lysate (Figure 2.4B,
upper panel).

Additionally, both halves of AKAP7γ, AKAP7γ(1-150) and

AKAP7γ(150-323), were able to pulldown AKAP7γ-EGFP from transfected cell
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lysate, revealing that each half of the protein participates in the homo-association
of AKAP7γ (Fig 2.4A).
To further refine the location of the binding sites, the human AKAP7γ
sequence was synthesized as 20-mer peptides with three amino acid offsets on
membranes using a Multipep automated peptide synthesizer, and then subjected
to overlay with bacterially purified, full length, S-tagged AKAP7γ (Figure 2.4C,
upper panel).

Using an HRP-conjugated anti-S tag antibody, binding was

observed to two regions; amino acids 43-98 and amino acids 202-296.
Importantly, the HRP-conjugated anti-S tag antibody did not detect any spots in
the absence of overlay with purified AKAP7γ (Figure 2.4C, lower panel). This
data offers further confirmation that there are two regions of interaction between
AKAP7γ and itself.

Dimerization of AKAP7γ can be detected in cells
The existence of two sites of interaction of AKAP7γ with itself suggests the
potential to form multimeric structures. This possibility was investigated via
photon counting histogram (PCH) analysis of AKAP7γ-EGFP expressed in live
HEK-293 cells. Photon counting histogram analysis is a method of fluorescence
correlation spectroscopy that allows for determination of the size (brightness, ε)
and concentration (number, n) of a given oligomer from fluctuations in signal
intensity. This technique uses standard confocal optics to create a measurement
volume on the order of 0.5fL. As fluorescent particles diffuse through the
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Figure 2.4 Mapping the sites in AKAP7γ responsible for oligomerization. A) Schematic depicting
AKAP7γ fragments used for pulldown experiments. B) Lysates from AKAP7γ-EGFP transfected
HEK-293 cells were subjected to pulldown assays using bacterially purified S-tagged
AKAP7 deletion fragments precharged on S-protein resin; AKAP7γ-150-323, AKAP7γ-1-150, fulllength AKAP7γ or AKAP7α. Anti-GFP antibody was used for detecting protein interactions by
western blot analysis (upper panel). Protein stain of the nitrocellulose membrane before western
blot analysis is shown in the lower panel. Input from the transfected cells (20µl) is shown in the
last lane. n=3. C) The full length AKAP7γ sequence was spotted as overlapping 20-mer peptides
with 3 amino acid shifts on cellulose membranes and subjected to overlay using S-tagged
AKAP7γ. Binding was detected by chemiluminescence using an HRP-conjugated S-protein
antibody (upper panel). The antibody did not detect any binding in the absence of S-tagged
AKAP7γ overlay (lower panel). n=4.
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measurement volume, their signal is detected by a highly sensitive detector such
as an avalanche photodiode. The change in signal intensity is dependent upon
the average number of particles within the volume (n) and the brightness of a
given particle (ε). At low average particle concentrations, the change in
fluorescence intensity resulting from a single particle entering or leaving the
volume is readily detected, while at high concentrations this change is less
detectable. Detection of the change in intensity over time yields a fluctuation
trace. The fluctuation trace (Figure 2.5A) is divided into small increments of time
(bins) and the signal intensity (counts) is averaged within each increment. The
average signal for each bin is then plotted as frequency vs. counts/bin to yield the
photon counting histogram (Figure 2.5A), which can be fit to determine the
brightness and concentration of the fluorescent particles present. Cells
expressing low yet detectable amounts of AKAP7γ-EGFP were selected for
analysis due to the dependence of signal variance on the inverse of the number
of particles present in the confocal volume. For each cell chosen, five regions
were selected from within the cytoplasm for analysis. Each region was measured
5 times for 10s per measurement. The data for each construct was fit globally
with either a single component model (EGFP monomer and dimer) or two
component model (AKAP7γ-EGFP) yielding a brightness value (ε) and
concentration for either one or two species respectively. This type of fitting allows
for the derivation of a single brightness value based upon the aggregate data
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Figure 2.5 Photon counting histogram detects dimerization of AKAP7γ in live cells. A) A
representative section of the fluctuation trace (above). The fluctuation trace is divided into 10ms
bins and plotted as a histogram of frequency vs. counts/bin (below). Fitting of the histogram yields
the concentration (number, n) and brightness (e) of the fluorescent particles. B) Data summary.
HEK-293 cells were transfected with monomeric EGFP, dimeric EGFP, or AKAP7γ-EGFP.
Selected cells were measured 5 times at 5 different positions within the cytosol for 10s per
measurement. Measurements exhibiting bleaching or other instabilities in fluorescence intensity
2
were excluded from analysis. Global fitting of the data produced near ideal fits (χ global of 1.0 is
ideal). Monomeric and dimeric EGFP were fit using a single component model, while AKAP7γ
was fit using a 2-component model allowing for the detection of both monomeric and dimeric
AKAP7γ-EGFP. *Average concentrations and [Dimer]/[Total] were determined from the 52
measurement in which the presence of dimer was detected.
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from all measurements of a given fluorescent construct, rather than averaging
individual values derived from each individual measurement. Global-fitting of the
EGFP monomer and dimer yielded brightness values of 9468 ± 72 (χ2reduced =
1.10) and 16967 ± 100 (χ2reduced = 1.14) respectively (Figure 2.5B). For AKAP7γEGFP 75 total measurements from 5 cells were best fit using a two component
model with brightness values constrained to 9500 and 17000 representing
monomer and dimer respectively (χ2 = 1.04). Of 75 total measurements included
in the analysis, dimer was detected in 52 measurements and in 42
measurements >10% of the total particles detected represent dimer (Figure 2.4B).
Among the 52 measurements that detect dimer, the average concentration of
monomer is 19.81±2.40nM and the average concentration of dimer is
3.99±0.06nM. On average, 20±0.3% of the particles detected is dimer, indicating
that 28.7% of AKAP7γ-EGFP is in the dimeric form. Based upon the
concentrations of monomer and dimer, the apparent Kd of dimerization falls in
the range from 78.8-126nM with an average of 98.4nM. This apparent Kd is
consistent with the kinetic data from SPR. Attempts to detect higher order
oligomeric structures by fitting AKAP7γ-EGFP data with larger brightness values
were unsuccessful. However, this does not exclude the possibility that higher
order AKAP7γ oligomers exist. The concentrations of higher order oligomers was
likely insufficient either for detection, or for discrimination from the population of
monomers and dimers. This evidence offers further confirmation that selfassociation of AKAP7γ occurs in live cells.
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Oligomerization of AKAP7γ functions to increase target phosphorylation
Our finding that AKAP7γ is able to form homo-dimers is interesting and
leads us to question the functional role of oligomerization. The two large regions
of interaction make it exceedingly difficult to disrupt AKAP7γ oligomerization.
Thus,

we

decided

to

test

the

possible

functional

significance

of

AKAP7γ oligomerization in silico. We created a compartmental deterministic
model that simulates the dynamics of the PKA regulatory (RIIα) and catalytic
subunits (Cα) in response to cAMP, both in the cytosol and on the endoplasmic
reticulum (ER) membrane. We chose to model the dynamics of AKAP7γ at the
ER due to recent work demonstrating localization of the scaffold at the ER in
cardiac myocytes (27). Included in the model is autophosphorylation of RIIα, as
this is documented as a key component for activation of Cα when complexed
with RIIα (10, 51, 64). In our model, it is assumed that the probability of activation
of all Cα subunits within an oligomer increases as the total number of activated
Cα subunits increases (Equation 1, methods). Active Cα subunits were modeled
to participate in the phosphorylation of a generic target protein X (X à pX)
existing on the ER membrane (Equation 2, methods). The time course of
formation of pX is shown for separate simulations that compare oligomeric states
from monomer to tetramer (Figure 2.6A). Upon stimulation of PKA activity, the
amount of pX increases in all cases. When the monomeric state (n=1) is
simulated, phosphorylation of our target protein occurs as it would if the feedforward assumption is not made. Removal of the stimulus leads to
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Figure 2.6 Oligomerization of AKAP7γ functions to increase target phosphorylation. A) Time
course of target protein X phosphorylation for each oligomeric state. An increase in cAMP
production is simulated from 0-100s resulting in activation of AKAP bound PKA and
phosphorylation of target protein X. The inset shows the change in [pX] from baseline to maximal
phosphorylation relative to the change in phosphorylation produced by the monomeric state.
B) Time course of target X phosphorylation for a mixture of monomer and dimer as measured via
PCH. The concentration of monomeric and dimeric AKAP complexes were adjusted so that
71.3% of the total AKAP exists as monomer and 28.7% exists as dimer. An increase in cAMP
production was simulated as above. The inset shows the change in [pX] from baseline to maximal
phosphorylation relative to 100% monomer.
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dephosphorylation of pX and return to baseline. Oligomerization of AKAP7γ
affects the baseline, magnitude, and speed of phosphorylation of protein X (Fig.
2.6A & 2.6B). The largest magnitude change of pX occurred in the dimeric state,
with larger order AKAP7γ oligomers exhibiting decreased magnitude change in
pX (Figure 2.6B). When the active scaffolded PKA population was adjusted to
reflect a mixture of monomeric and dimeric states according to our PCH data, the
baseline phosphorylation level remains low (8.26 molecules/µm2) while the
magnitude change in pX increases by 76% in comparison to monomer only
(Figure 2.6A & 2.6B). This analysis demonstrates the possible impact of AKAP7γ
oligomerization on the rate of PKA substrate phosphorylation.

Discussion
Significant work has demonstrated the impact of scaffolding on the
organization of signaling proteins into discrete focal points of subcellular enzyme
activity (65).

However, information regarding the molecular architecture of

scaffolds and their influence on phosphorylation events is currently lacking. Here,
through the use of a combination of protein biochemistry, fluorescence
correlation spectroscopy and computational modeling, we deciphered that the
scaffolding protein AKAP7γ dimerizes in vitro and in cells. Our ability to detect
dimerization via PCH indicates that dimerization is occurring in live cells.
Importantly, computational modeling suggests that dimerization may act to
increase target phosphorylation. These findings represent a previously
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unappreciated mechanism involved in the configuration of AKAP complexes and
the regulation of protein phosphorylation.
Oligomeric proteins, composed of two or more polypeptide chains,
represent a major fraction of total cellular proteins (55). Interestingly, a search of
the BRENDA enzyme database (http://www.brenda.uni-koeln.de/) reveals that of
the total 452 human enzymes with known subunit composition, over 300 exist in
multimeric

states.

Oligomerization

of

signaling

proteins

is

a

common

phenomenon that occurs in many signal transduction networks. This is especially
true at the level of the receptor, in which numerous examples of oligomerization
exist (57, 66). Recent evidence suggests intracellular scaffolding proteins also
oligomerize (67, 68). Several recent reports have demonstrated homooligomerization of AKAP5, AKAP12 and AKAP-Lbc (69-71). Dimer formation of
these AKAPs is mediated by direct protein-protein interactions. A leucine zipper
motif in the N-terminus of AKAP-Lbc dictates the interaction while multiple
domains of AKAP5 are required for dimerization (69, 71). As we have shown,
AKAP7γ dimerization also occurs via direct interaction. Determination of the
binding kinetics via SPR reveals that AKAP7γ forms a dimer via high-affinity
interaction that occurs at two sites. We were able to detect dimerization of
AKAP7γ in cells via PCH and estimate the affinity of interaction from the
concentrations of monomer and dimer. The estimated Kd based on our PCH
result is approximately 98nM, which is remarkably similar to the Kd of site-two
(79.7nM) from the fit of our SPR data. Although the affinity of site-one from the
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SPR analysis is much higher, it is possible that interaction of AKAP7γ with
endogenous binding partners in the cell alters the affinity of this site, or that
binding simply cannot occur due to steric hindrance. Our efforts to map the sites
of binding confirm that two major regions of interaction exist. Interestingly, the
crystal structure of the common central domain contained in the long AKAP7
isoforms (amino acids 76-292 of AKAP7δ) does not indicate oligomerization of
the AKAP (72). This structure lacks the N-terminus of AKAP7γ, which is predicted
to exist in an unordered arrangement, according to FOLDindex©. Several AKAPs
have a natively disorganized, unfolded configuration that is hypothesized to aid in
the docking of a multitude of binding partners (69, 70, 72).

However, this

unstructured flexibility also significantly hinders conventional structural analysis.
Hence, this N-terminal domain of AKAP7γ may contribute significantly to its
oligomerization. In fact, our peptide array analysis demonstrates that the majority
of the interacting sequence from 43-98 is not contained in the original crystal
structure.

Other possible mechanisms include post-translational modification

driven interactions, and coiled-coil interactions (73-75). Analysis of the AKAP7γ
sequence using the PredictProtein web site as well as both MARCOIL and
LOGICOIL web resources support these possibilities for AKAP7γ. Testing these
potential mechanisms for oligomerization will help in delineating the means of
AKAP7γ complex formation.
Signaling proteins utilize oligomerization to enhance their known cellular
functions. One of the better-studied examples is the receptor tyrosine kinase
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(RTK). Dimerization of RTKs results in activation and autophosphorylation of
tyrosine residues on the intracellular domain of the receptor (76, 77). This step
initiates the recruitment of other signaling proteins and propagation of signals
from the receptor to intracellular targets. Though often thought to function in a
monomeric state, a number of G-protein coupled receptors (GPCRs) have been
shown to form both homo- and hetero-dimers, often resulting in enhanced activity
(57).
The consequences of AKAP oligomerization are still unclear, but may
affect multiple processes. Mass spectrometry analysis of the AKAP5 complex
suggests that upon dimerization, AKAP5 associates with four calcineurin
phosphatase heterodimers, and two calmodulin molecules (69). By increasing
the concentration of the phosphatase in a localized area, it is suggested that
AKAP5 can generate specific pools of second messenger-mediated events at the
plasma membrane. How this change in stoichiometry affects substrate
dephosphorylation or kinetics of enzyme activation has not been investigated.
However, other studies of the native AKAP5 complex in hippocampal neurons
suggest this increase in stoichiometry is an in vitro artifact, as no increase in
stoichiometry was detected in vivo (78). Oligomerization may also affect
regulation of intrinsic enzymatic activity of an AKAP. AKAP-Lbc is a guanine
nucleotide exchange factor (GEF) for RhoA (79).

Disruption of AKAP-Lbc

dimerization dramatically increased its GEF activity, suggesting that oligomer
formation acts to limit the basal activity of the AKAP (71). However, AKAP7γ
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does not display any known intrinsic enzymatic activity, suggesting this
mechanism is not applicable.
To explore the possible functional significance of AKAP7γ oligomerization,
we created a computational model of PKA scaffolding. Significant work has
demonstrated that release of active Ca subunit from the PKA holoenzyme
requires not only cAMP binding to the RIIα subunit, but also autophosphorylation
of RIIα (16-18). This leads us to hypothesize that in the context of an AKAP7γ
oligomer, release of a single Cα subunit can potentiate the release of additional
Cα via phosphorylation of RIIα present in the oligomer. In the monomeric state, a
single Cα can stimulate release of only one extra Cα subunit, but, in a dimeric or
oligomeric state, release of additional Cα subunits is possible. This double
negative feedback loop ultimately increases substrate phosphorylation due to the
increased probability of phosphorylation resulting from increased Cα release
(Figure 2.7). This is simulated by defining activation of PKA in the AKAP7γ
complex as a probability function in which the chance of activating all Cα
subunits increases as the number of active Cα subunits within the complex
increases (Eq. 1). The model suggests that the physiologic consequence of
AKAP7γ oligomerization could be increased baseline phosphorylation, increased
magnitude of phosphorylation in comparison to the monomeric state, and
increased speed of phosphorylation. For the distribution of monomeric and
dimeric AKAP7γ derived from our PCH experiment, the model predicts a 1.91 fold
increase in baseline phosphorylation and a 1.77 fold increase in magnitude of
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Figure 2.7 Double negative feedback model of PKA activation A) Double negative feedback loop.
In the resting state, Cα is inhibited by RIIα. However, once Cα is activated by cAMP it is able to
phosphorylate RIIα at Ser-99, which prevents RIIα from inhibiting Cα. B) Illustration of the double
negative feedback mechanism occurring within a hypothetical trimeric AKAP complex. AKAP
(light blue helix) recruits PKA (R homodimer, orange; C, light yellow) to a membrane (blue)
associated target X (red). In the context of this AKAP oligomer, activation of a single Cα is likely
to phosphorylate RIIα within the complex leading the release of further Cα. This process feeds
forward, increasing the probability that all Cα within the complex will become active as each
additional Cα is activated. The increased amount of active Cα also increases the probability of
target phosphorylation.
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phosphorylation in comparison to monomer only. It is important to note that our
finding does not result from an increase in AKAP7γ or PKA concentrations at the
ER membrane, it reflects the consequence of oligomerization on PKA activity. In
all simulations the total amount of PKA scaffolded to the membrane by AKAP7γ
remains the same. The double negative feedback behavior of Cα activation has
the potential for interesting consequence when considered in a spatial context.
The free diffusion of active Cα may permit its interaction with AKAP7γ complexes
that exist beyond the location of its complex of origin. This could enable the
spatial spread of PKA activation and target phosphorylation similar to that of a
calcium spark. Spatial spread of the PKA signal in this manner would depend
upon many factors including: the diffusion coefficient of Cα, the density of AKAP
complexes, the ability of Cα to re-associate with RIIα, and the spatiotemporal
fluctuation in cAMP concentration.
We have discovered an additional component of the AKAP7γ signaling
complex

and

demonstrated

that

dimerization

of

AKAP

may

impact

phosphorylation of PKA substrates. As several PKA targets of AKAP7γ have
been identified, including PDE4D, the PP1 inhibitor I-1 and the cardiac calcium
regulatory protein phospholamban, AKAP7γ oligomerization has the possibility of
effecting phosphorylation of these endogenous substrates.

	
  

49

Chapter 3
Phosphorylation-state dependent interaction between AKAP7δ/γ and
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Abstract
Changes in heart rate and contractility in response to sympathetic stimulation
occur via activation of cAMP dependent protein kinase A (PKA), leading to
phosphorylation of numerous substrates that alter Ca2+ cycling. Phosphorylation
of these substrates is coordinated by A-kinase anchoring proteins (AKAPs),
which recruit PKA to specific substrates (29). Phosphorylation of the PKA
substrate phospholamban (PLB) is a critical determinant of Ca2+ re-entry into the
sarcoplasmic reticulum and is coordinated by AKAP7δ/γ (27, 43). Here, we
further these findings by showing that phosphorylation of PLB requires interaction
with

AKAP7δ/γ

and

that

this

interaction

occurs

only

when

PLB

is

unphosphorylated. Additionally, we find that two mutants of PLB (R9C and Δ14),
which are associated with dilated cardiomyopathy in humans, prevent
association with AKAP7δ/γ and display reduced phosphorylation in vitro. This
finding implicates the AKAP7δ/γ-PLB interaction in the pathology of the disease
phenotype. Further exploration of the AKAP7δ/γ-PLB association demonstrated a
phosphorylation state-dependence of the interaction. Computational modeling
revealed that this mode of interaction allows for low concentrations of AKAP and
PKA (100-200nM) to regulate the phosphorylation of high concentratins of PLB
(50µM). Our results confirm that AKAP7δ/γ binding to PLB is important for
phosphorylation of PLB, and describe a novel phosphorylation state-dependent
binding mechanism that explains how phosphorylation of highly abundant PKA
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substrates can be regulated by AKAPs present at ~100-200 fold lower
concentrations.
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Introduction
The heart responds to an increase in sympathetic stimulation via
activation of the cAMP-dependent protein kinase PKA, leading to phosphorylation
of several key substrates. These substrates mediate Ca2+ entry, release, and
uptake into intracellular stores. Phosphorylation therefore allows the heart to
increase the force contraction and the rate of relaxation by changing the kinetics
of the Ca2+ transients that underlie these physiological events.

Importantly,

several key studies have demonstrated that PKA must be compartmentalized
with its substrate in the heart in order for phosphorylation to occur (80).

This is

accomplished via A-kinase anchoring proteins (AKAPs), a class of scaffolding
proteins that compartmentalize PKA with its substrates, thereby forming a
microdomain of PKA activity. Importantly, disruption of PKA anchoring using
global AKAP/PKA disrupting peptides greatly impacts the contractile response of
the myocyte to sympathetic stimulation, demonstrating the importance of AKAPs
for regulation of cardiac Ca2+ dynamics (23, 81).
A key AKAP that plays a role in the regulation of cardiac Ca2+ dynamics is
AKAP7 (82). This AKAP has four splice variants (α, β, γ and δ), with a range of
molecular weights from 18 to 50 kDa (32). AKAP7δ/γ plays an important role in
the rate of relaxation of the heart via mediating the phosphorylation of the cardiac
protein phospholamban (PLB) (27). In its unphosphorylated state, PLB binds to
the Sarcoplasmic Reticulum Ca2+-ATPase (SERCA2) pump and decreases pump
action, thus providing a rate-limiting step in the cardiac contraction/relaxation
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cycle. Phosphorylation of PLB disrupts the PLB/SERCA2 interaction, thereby
accelerating Ca2+ re-uptake into cardiac stores and allowing for an increase in
the rate of relaxation. Importantly, peptide-based disruption of the AKAP7δ-PLB
interaction in the rat myocyte significantly attenuates the sympathetic-promoted
phosphorylation of the protein and the increase in Ca2+ re-uptake associated with
stimulation (27). It is important to note that AKAP7δ is replaced by AKAP7γ in
the human and mouse myocyte (44). Hence, it has been suggested that this
interaction could be used as a potential drug target in heart failure patients (83).
A number of AKAP7δ/γ binding partners with the capacity to influence
PLB phosphorylation have been identified including protein kinase C (PKC),
protein phosphatase-1, inhibitor-1 (I-1), and phosphodiesterase 3A (PDE3A) (49,
84, 85). This evidence provides us with the key elements of the AKAP7δ/γ
signaling microdomain, which may control PLB phosphorylation. However, one
particularly critical question exists: how does a low abundance protein like
AKAP7δ/γ regulate phosphorylation of a very high abundance protein like PLB?
This question was eloquently posed by Don Bers in his 2002 review of cardiacexcitation contraction coupling, commenting “…it is less clear how targeting
would practically work for phospholamban and troponin I phosphorylation (as
compared with ICa or RyR). This would require very high amounts of the various
anchoring and signaling proteins because troponin I and phospholamban are
present at 50µM or higher concentrations and are dispersed widely in the cell
(86).”
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The implied assumption of AKAP microdomain signaling is that AKAPs
remain bound to their respective PKA substrates regardless of the state of the
complex. If true, such a mechanism would require high concentrations of both
AKAP and its binding partners that is similar to that of the PKA substrates – but
the cellular concentration of PKA is not nearly as high as PLB, nor are the
concentrations of AKAP7δ/γ or its other binding partners (Protein phosphatase 1,
Inhibitor-1 and Phosphodiesterase4D3) (47, 49, 87-89). However, it is clear that
the AKAP plays an important role in the phosphorylation of PLB (90). Here, we
confirm that binding of PKA to AKAP7δ/γ is required for PLB phosphorylation and
that deletion of the PKA binding domain on the AKAP7 results in a significant
reduction in PLB phosphorylation. Importantly, several human mutants of PLB,
which are known to exhibit decreased phosphorylation and are associated with
dilated cardiomyopathy, do not interact with AKAP7δ/γ, suggesting that the PLBAKAP7δ/γ interaction is necessary for phosphorylation. Therefore, the question
remains: how are these AKAP-binding requirements compatible with the efficient
phosphorylation of large amounts of PLB? We hypothesized that this could be
explained by our newly observed phosphorylation state-dependent binding of
AKAP7δ/γ to PLB. Here, we show that the high affinity association between
AKAP7δ/γ and PLB is lost upon phosphorylation of PLB. A computation model of
the detailed biochemical kinetics of the pathway showed that if state-dependent
binding

is

included

in

the

reaction

network,

phosphorylation

of

high

concentrations of PLB is possible at low concentrations of both AKAP7δ/γ and
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PKA, consistent with the observed results (90). Importantly, our experimental
findings and kinetic analysis provide a mechanistic hypothesis of AKAP7δ/γ
complex signaling in cardiac myocytes that reconciles the problem with disparity
of complex component concentrations.

Experimental Methods
Antibodies
The following primary antibodies were used for immunoblotting: mouse
monoclonal Phospholamban (Millipore; 1:1000 dilution), polyclonal phosphorphospholaman serine 16 (Millipore; 1:500), mouse monoclonal GFP (Santa Cruz
Biotechnology; 1:500 dilution), polyclonal mCherry (Thermo Scientific Pierce;
1:3000 dilution), monoclonal PKA RIIα subunit (Santa Cruz Biotechnology; 1:500).
Immunoprecipitations were carried out using the following antibodies: polyclonal
AKAP7 (Sigma; 5µg), mouse monoclonal GFP (Santa Cruz Biotechnology; 5µg),
mouse monoclonal Phospholamban (Millipore; 3µg)

Expression constructs
The human phospholamban construct was obtained from Origene and amended
with EcoRI/BamHI restriction sites using PCR, and subcloned into the peGFP-N1
vector.

Mutant phospholamban constructions were made by site directed

mutagenesis.
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Cell Transfection and Immunoprecipitation
HEK293 cells were transfected at 50-70% confluency in 60mm plates using the
calcium phosphate method with 6 µg of each plasmid DNA. Cells were treated
with various drugs for the time specified, and cell lysate was collected in 0.5ml
HSE buffer (HEPES, pH 7.4, 150mM NaCl, 5mM EDTA, 1% Triton X-100 and
protease inhibitors).

Supernatants were incubated overnight at 4°C with the

indicated antibody and 15ml of prewashed protein A-or G-agarose. Following
extensive washing, captured proteins were solubilized in 2X sample buffer and
analyzed by immunoblot.
Rat heart extract was prepared as previously described (26, 91).
Immunoprecipitating antibodies were added to 500µl of extract along with 13µl
protein agarose. After an overnight incubation followed by extensive washing,
captured proteins were analyzed by immunoblot.

In vitro Phospholamban phosphorylation assays
Various PLB peptides (1µg) were incubated in kinase buffer (50mM Tris-HCL pH
7.5, 5mM MgCl2) containing 100mM ATP, 5mM [γ-32]ATP and 800 units of
purified PKA catalytic subunit (NEB). After a 15 minute incubation at 30°C, the
reaction mixture was spotted onto phosphocellulose strips and washed five times
in 75mM phosphoric acid. Filters were air dried and counted.
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Rat neonatal myocyte culture
Myocytes were prepared from 2 day old Sprague-Dawley rats, as previously
described. Cell were plated in Dulbecco’s Modified Eagle medium (DMEM)with
17% Media 199, 1% penicillin/streptomycin solution, 10% horse serum and 5%
fetal bovine serum (FBS) at 125,000 per cm2. After an overnight incubation in
plating medium, the myocytes were maintained in culture for up to one week in
maintenance medium (79% DMEM, 20% Media 199, and antibiotic).

Cells were

stimulated with the various drugs as described.

Surface Plasmon Resonance
SPR

analysis

was

performed

using

a

BIAcore

T100.

Biotinylated-

Phospholamban peptide (Chi Scientific) was covalently immobilized using NHS
(N-hydroxysuccinamide)

and

EDC

[1-ethyl-3-(3-

(dimethylamino)propyl)carbodiimide] (Biacore amine coupling kit) to the surface
of a sensor chip (BIAcore type CM5). The amount of ligand bound (in resonance
units, RUs) was 300 RU. AKAP7γ protein analyte was diluted at increasing
concentrations (25–100 nM) in HBS buffer (10 mM HEPES (pH 7.4), 150 mM
NaCl, and 0.005% Surfactant P20) and injected over the sensor surface at a flow
rate of 30 µL/min for 300 seconds. Post injection phase, dissociation was
monitored in HBS buffer for 300 seconds at the same flow rate. The surface was
regenerated between injections using 10 mM NaCl at a flow rate of 50 µL/min for
30 seconds. Sensorgrams were all processed by BIAcore T100 evaluation
software.
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GST-RII pulldown assay
Beads charged with RIIα-GST fusion protein were incubated with isolated cell
lysate transfected as described above. After an overnight incubation at 4C with
shaking, beads were washed extensively and captured proteins were solubilized
in 2X sample buffer and analyzed by immunoblot.

Computational Modeling of the AKAP7-Phospholamban complex.
An ordinary differential equation (ODE) model of PLB phosphorylation by
AKAP7δ/γ bound PKA was implemented using the Virtual Cell modeling software.
The reaction network is composed two basic modules; 1) cAMP production and
PKA activation and 2) AKAP7δ/γ binding and phosphorylation of PLB with a total
of 18 species and 14 reactions (Table 1, Fig S1). Activation of AC via association
with Gs in module 1 results in the production of cAMP that binds PKA (R2C2)
resulting in sequential dissociation of each of two catalytic subunits (C). Free C is
able to phosphorylate Gs within the GsAc complex resulting in the inhibition of
cAMP production and, in conjunction with the activity of PDE, the return of cAMP
levels to baseline. Due to the high affinity interaction of cAMP with the PKA
regulatory subunit (R), C does not reassociate with R to form PKA (R2C2)
following cAMP stimulation. In order to return PKA activity to baseline following
stimulation we allowed cAMP bound R (R2_cAMP) to be stripped of cAMP by
PDE (reference). In the second module of the reaction network PLB associates
with AKAP to form a complex (AKAP_PLB) followed by phosphorylation of PLB
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(AKAP_pPLB). All AKAP is bound to PKA derived from the total pool of PKA in
module 1. Since AKAP bound PKA activity represents only a fraction of the total
PKA activity, the total AKAP-PKA activity is defined by the following equation:
𝐸 = 2 ∗ 𝐴𝐾𝐴𝑃_𝑃𝐿𝐵 ∗

𝐶
2 ∗ 𝑅2𝐶2 + 𝑅2𝐶1 + 𝐶

where E represents the total amount of enzyme (active PKA) from the AKAP
bound pool of PKA that is available to participate in the phosphorylation of PLB
which, is defined by standard Michaelis-Menten kinetics:
𝑝𝑃𝐿𝐵 =   

𝐸 ∗ 𝑘!"# ∗ [𝐴𝐾𝐴𝑃_𝑃𝐿𝐵]
(𝐾𝑚 + 𝐴𝐾𝐴𝑃_𝑃𝐿𝐵 )

To simulate the difference between phosphorylation state-dependent (AKAP
does not bind pPLB) and phosphorylation state-independent (AKAP binds both
PLB and pPLB) the reverse rate for the interaction of AKAP and pPLB was
modulated so that AKAP bound pPLB with either equal or lower affinity than PLB.
For state-independent binding, the affinity of AKAP for pPLB is the same as in
the non-phosphorylated state and for state-dependent binding the forward rate
was increased. For state-dependent binding to PLB the reverse rate of the
AKAP-pPLB interaction was increased by a factor of 1000, changing the affinity
from 13.3nm to 13.3µM. The model is available in the public biomodels folder of
the Virtual Cell software.
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Results
AKAP7γ directly binds to phospholamban
Due to conflicting evidence demonstrating the importance of AKAP7δ/γ for
phospholamban (PLB) phosphorylation (27, 90), we investigated the dynamics of
AKAP7δ/γ binding to PLB as a possible regulatory function of phosphorylation.
To begin with, we confirmed previous findings that AKAP7δ/γ binds directly to
PLB (27). As shown in Figure 3.1A, PLB co-immunoprecipitated with AKAP7δ/γ
from isolated rat heart extract, but not with control IgG, demonstrating that these
two proteins form a complex in cardiac myocytes. Next, we investigated if this
interaction was specific for the cardiac myocyte, or if association could be
detected in a heterologous system. HEK293 cells were transfected with plasmids
expressing

mCherry-AKAP7γ

phospholabman.

in

the

presence

and

absence

of

GFP-

GFP was immunoprecipitated and the association of

AKAP7γ was determined by Western blot analysis (Figure 3.1B). Importantly, coprecipitation of mCherry-AKAP7γ was only seen in cells expressing GFP-PLB,
demonstrating the specificity of the interaction. To further these findings and
examine the kinetic properties of the interaction, we performed surface plasmon
resonance (SPR). As the domain on phosholamban for binding to AKAP7γ is
maintained in the first 21 amino acids, we immobilized a peptide mimicking this
domain on a CM5 sensor chip. Varying concentrations of purified AKAP7γ were
used to determine the dynamics of the interaction. As shown in Figure 3.1C, we
confirmed a direct interaction between phospholamban and AKAP7γ with an
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Figure 3.1 Direct cellular interaction between AKAP7δ/γ and phospholamban.
A) AKAP7γ was immunoprecipitated from rat heart extract and association of PLB was
determined by Western Blot. n=3. B) mCherry Western blot analysis of anti-GFP
immunoprecipitates isolated from HEK-293 cells co-transfected with mCherry-AKAP7γ in the
presence and absences of GFP-PLB (upper panels). To confirm immunoprecipitation of equal
amounts of GFP-PLB, the nitrocellulose membranes were also probed for GFP using a
monoclonal anti-GFP antibody (middle panel). Lower panels depict mCherry and GFP Western
blot analysis of the input (20µL) from each condition. n=3. C) SPR was performed by immobilizing
a peptide containing the first 21 amino acids of PLB (150RUs) on a CM-5 chip and measuring the
response when passing over a range of concentrations (25-100nM) of AKAP7γ. Forward and
reverse rates of binding and binding affinity were determined by fitting of the sensorgram with
BIAcore T100 evaluation software.
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affinity of 13.3nM. Analysis of the fit of the interaction suggests one site of
interaction. Taken together, these data confirm the original observation
demonstrating a direct association of AKAP7γ with phospholamban that can be
isolated from cardiac myocytes.
PKA bound to AKAP7δ/γ is responsible for phosphorylation of phospholamban
The primary purpose of AKAPs is to co-localize PKA and its substrate via
formation of a multi-component signaling complex, resulting in enhanced
substrate phosphorylation. Therefore, we next examined the necessity of PKA
binding to AKAP7δ/γ for PLB phosphorylation. To investigate this association in
an endogenous tissue, PLB was immunoprecipitated from rat heart lysate, and
association with PKA was determined in the presence or absence of the
AKAP/PKA disrupting peptide AKAP-IS (Figure 3.2A) (15). Disruption of PKA
anchoring using the AKAP-IS peptide decreased association of the PKA RII
subunit with PLB. Importantly, incubation of a control peptide did not significantly
affect PKA/PLB interaction, demonstrating that PKA associates with PLB via
interaction with AKAP.

To determine the role of AKAP7γ in mediating this

association, HEK293 cells were transfected with GFP-PLB and either wild-type
mCherry-AKAP7γ, or one lacking the PKA binding domain (mCherry-DPKAAKAP7γ). Lysate isolated from these cells was subjected to pulldown analysis
using GST-tagged PKA RIIα subunit.

This is a common technique used to

isolate AKAP complexes from various tissues, as the RII subunit will pulldown the
AKAP and all AKAP-associated proteins (49, 69). As shown in Figure 3.2B,
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Figure 3.2 AKAP7δ/γ anchors PKA to the phospholamban complex to enhance phosphorylation.
A) PLB was immunoprecipitated from rat heart lysate. Following extensive washing, the
immunoprecipitates were incubated with the AKAP/PKA disrupting peptide AKAP-IS (10µM) or
control peptide (10µM) for 30 minutes while rocking. After another round of washing, association
of the regulatory subunit of PKA was determined by Western blot. B) HEK-293 were transfected
with GFP-PLB and either wild-type mCherry-AKAP7γ, or one deficient in the PKA binding domain
(mCherry-ΔPKA-AKAP7γ). Isolated lysates were subjected to pulldown assays using bacterially
purified GST-tagged PKA RII subunit precharged on Glutatione-agarose; Both GFP and mCherry
antibodies were used for detecting PLB and AKAP7γ interactions, respectively (upper panel).
Protein stain of the nitrocellulose membrane before Western blot analysis is shown in the middle
panel. Input from the transfected cells (20µl) is shown in the bottom panels. n=3. C) HEK-293
were transfected with GFP-PLB and either wild-type mCherry-AKAP7γ, or one deficient in the
PKA binding domain (mCherry-ΔPKA-AKAP7γ). Cells were stimulated with 100µM Isoproterenol
for 5 minutes before cell lystate was isolated and loaded onto and SDS-PAGE gel.
Phosphorylation of PLB at Serine 16 was determined using a phospho-specific antibody (upper
panel). Total expression of the proteins is shown in the lower panels using both GFP and
mCherry antibodies to detect PLB and AKAP7γ, respectively. n=3
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GFP-PLB only associated with the PKA subunit in the presence of full-length
AKAP7γ. However, when the PKA binding domain was deleted from the AKAP,
GST-RIIα could no longer pulldown PLB, demonstrating the importance of PKA
anchoring to AKAP7γ. Taken together, these results implicate AKAP7γ for linking
the kinase to the PLB complex.
Next, we investigated the functional significance of this interaction for
regulation of PLB phosphorylation. We first performed analogous experiments to
those outlined in Figure 3.2B, and looked at the role of AKAP7γ-bound PKA on
PLB phosphorylation. As shown in Figure 3.2C, expression of the anchoring
protein dramatically heightened PLB phosphorylation. However, when the PKA
binding domain was deleted from the AKAP, this enhancement was lost,
suggesting that the kinase must be attached to the AKAP for this effect.

Described human mutations of phospholamban contained in the AKAP7δ/γ
binding domain decrease complex formation, thereby reducing phosphorylation
Multiple mutations of PLB have been identified and linked to familial
dilated cardiomyopathy.

At least two of these mutations are found in the

AKAP7δ/γ binding domain, suggesting these mutation may affect the ability of
PLB to bind to the AKAP7δ/γ (Schematic diagram shown in Fig 3.3A). Mutation of
Arginine 9 to Cystine (PLB-R9C) displays a dose-dependent inhibition of
SERCA2a and significantly decreased phospho-PLB (92). The other mutation
found in the AKAP7δ/γ binding region is a deletion of Arginine 14 (PLB-Δ14),
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which exhibits super-inhibition of SERCA2a activity, correlating with decreased
PLB phosphorylation (93). To test the importance of AKAP7δ/γ binding to PLB
for the phosphorylation of PLB, we utilized these mutations to block association.
We investigated whether or not these mutations affect the ability of the complex
to form in a cellular environment.

AKAP7γ was coexpressed in HEK293 with

wild-type PLB-GFP, or one of the mutated isoforms (PLB-R9C-GFP or PLB-Δ14GFP). The PLB-GFP complex was isolated and association of AKAP7γ-mCherry
was determined by Western Blot.

As shown in Figure 3.3B, both mutations

significantly decreased the co-precipitation of AKAP7γ, suggesting that a
decrease in the AKAP7γ binding affinity measured in these mutants results in
decreased association of AKAP7γ with the protein in a cellular context.
Importantly, the decrease in complex formation seen with the PLB mutants
should reduce the concentration of PKA found in the PLB complex. To test this
hypothesis, AKAP7γ was coexpressed in HEK293 with wild-type PLB-GFP, or
one of the mutated isoforms (PLB-R9C-GFP or PLB-Δ14-GFP). Cell lysate was
subjected to GST-RII pulldown, and association of GFP-PLB was measured. In
confirmation of our findings, wild-type PLB associates with the PKA subunit when
co-expressed with AKAP7γ (Figure 3.3C). However, both PLB mutations showed
decreased association with the GST-RII, suggesting mutation of PLB in the
AKAP7δ/γ binding domain decreases complex formation and reduces PKA
association with PLB. As our hypothesis states that AKAP7δ/γ anchored PKA
mediates the phosphorylation of PLB, the decrease in complex
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Figure 3.3 Described human mutations of phospholamban disrupt AKAP7γ binding
A) Schematic depiction of the mutations found in phospholamban that are found in the AKAP7δ/γ
binding domain. B) mCherry Western blot analysis of anti-GFP immunoprecipitates isolated from
HEK-293 cells co-transfected with mCherry-AKAP7γ and either wild-type GFP-PLB, or one of the
mutated isoforms (PLB-RC9-GFP, or PLB-Δ14-GFP, upper panels). To confirm
immunoprecipitation of equal amounts of GFP-PLB, the nitrocellulose membrane was also probed
for GFP using a monoclonal anti-GFP antibody (middle panel). Lower panels depict mCherry and
GFP Western blot analysis of the input (20µL) from each condition. n=3. C) HEK-293 were
transfected with mCherry-AKAP7γ and either wild-type GFP-PLB, or one of the mutated isoforms
(PLB-RC9-GFP, or PLB-Δ14-GFP, upper panels). Isolated lysates were subjected to pulldown
assays using bacterially purified GST-tagged PKA RII subunit precharged on Glutatione-agarose;
Both GFP and mCherry antibodies were used for detecting PLB and AKAP7γ interactions,
respectively (upper panel). Protein stain of the nitrocellulose membrane before Western blot
analysis is shown in the middle panel. Input from the transfected cells (20µl) is shown in the
bottom panels. n=3. D) HEK-293 were transfected with mCherry-AKAP7γ and either wild-type
GFP-PLB, or one of the mutated isoforms (PLB-RC9-GFP, or PLB-Δ14-GFP. Cells were
stimulated with 100µM Isoproterenol for 5 minutes before cell lystate was isolated and loaded
onto and SDS-PAGE gel. Phosphorylation of PLB at Serine 16 was determined using a phosphospecific antibody (upper panel). Total expression of the proteins is shown in the lower panels
using both GFP and mCherry antibodies to detect PLB and AKAP7γ, respectively. n=3 E) PLB
peptides (1µg) were incubated in kinase buffer (50 mM Tris-HCL pH 7.5, 5 mM MgCl2) containing
-32
100 mM ATP, 5 mM [γ ]ATP and 800 units of purified PKA catalytic subunit (NEB). After a 15
inute incubation at 30°C, the reaction mixture was spotted onto phosphocellulose strips and
washed five times in 75 mM phosphoric acid. Filters were air dried and counted.
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formation seen with the mutated isoforms of PLB should therefore result in a
decrease in phosphorylation of the protein. To test this hypothesis, AKAP7δ/γ
was coexpressed in HEK293 with wild-type PLB-GFP, or one of the mutated
isoforms (PLB-R9C-GFP or PLB-Δ14-GFP). Cells were stimulated with 100nM
Isoproterenol for 5 minutes, and phosphorylation of PLB was determined by
Western Blot analysis (Figure 3.3D). In conjunction with those results seen in
both transgenic animals and human patients (92, 93), less phosphorylation was
seen with the mutated isoforms of PLB. This finding correlates with the
decreased PKA association within the mutant complexes due to deceased
affinities for AKAP7γ, suggesting that one mechanism for the attenuation of
phosphorylation of the mutant PLB isoforms is a significant decrease in the
localization of the kinase to the complex. However, it is plausible that this effect
may result from a decreased ability of these mutated isoforms to be
phosphorylated by the kinase and not a disruption in the localization of the kinase
to the PLB complex. To test this, peptides mimicking the first 21 amino acids of
wild-type PLB, PLB-R9C or PLB-Δ14 were subjected to an in vitro kinase assay.
As shown in Figure 3.3E, all peptides were able to be phosphorylated by the
kinase to a similar extent, suggesting the decrease in phosphorylation of the
mutated PLB isoforms seen in the exogenous system is not due to a lack of
ability of the kinase to phosphorylate the mutated isoforms. Taken together, the
data shown in Figure 3.3 supports the hypothesis that by linking the kinase to its
substrate PLB, AKAP7δ/γ mediates phosphorylation of PLB.
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Figure 3.4 Phosphorylation of PLB significantly decreases the affinity for AKAP7δ/γ. A) HEK-293
were transfected with GFP-PLB and mCherry-AKAP7γ. Cells were stimulated with 100µM
Isoproterenol for 5 minutes and the PLB complex was isolated by immunoprecipitation using antiGFP. Association of AKAP7γ was determined by Western blot using anti-mCherry (upper panels).
To confirm immunoprecipitation of equal amounts of GFP-PLB, the nitrocellulose membrane was
also probed for GFP using a monoclonal anti-GFP antibody (middle panel). Total expression of
the proteins is shown in the lower panels using both GFP and mCherry antibodies to detect PLB
and AKAP7γ, respectively. Phosphorylation of PLB at Serine 16 in total lysate was determined
using a phospho-specific antibody (upper panel). n=3 B) Rat neonatal cardiac myocytes were
stimulated with 10µM Isoproterenol for 5 minutes and the PLB complex was isolated by
immunoprecipitation. Association of AKAP7δ/γ was determined by Western blot (upper panel).
Total expression of the proteins is shown in the lower panels. Phosphorylation of PLB at Serine
16 in total lysate was determined using a phospho-specific antibody (upper panel). n=3
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Phosphorylation of phospholamban decreases the affinity for AKAP7δ/γ binding
Contained in the AKAP7δ/γ binding domain on PLB is the PKA
phosphorylation site. We therefore proposed that phosphorylation of PLB would
decrease the ability of the AKAP to interact with the protein.

To test this

hypothesis, we began by defining the change in affinity between phosphorylated
PLB and non-phosphorylated PLB using SPR.

We immobilized a peptide

mimicking the first 21 amino acids of either wild-type PLB, or one that is
permanently phosphorylated at Serine 16 to a CM5 sensor chip, and then
determined the kinetic strength of the two interactions using varying
concentrations

of

purified

AKAP7γ. As

shown

in

Figure

3.4A,

when

phosphorylated, the affinity of AKAP7γ and PLB is below the limit of detection,
suggesting a low affinity binding. To confirm this finding in a cellular context,
HEK293 cells were transfected with plasmids expressing mCherry-AKAP7γ and
GFP-PLB. After a 15 minute stimulation with 100nM Isoproterenol, GFP was
immunoprecipitated and the association of AKAP7γ was determined by Western
blot analysis (Figure 3.4B). Importantly, co-precipitation of mCherry-AKAP7γ was
dramatically decreased under conditions that result in phosphorylation of PLB.
These findings were confirmed in an endogenous setting. Rat neonatal myocytes
were stimulated with 10µM Isoproterenol for 15 minutes followed by
immunoprecipitation of phospholamban and blotting for AKAP7γ. Association of
AKAP7γ with PLB was not detected following isoproterenol stimulation. Taken

	
  

70

together, these findings suggest that the AKAP7δ/γ interaction with PLB is
dispersed upon activation of PKA and phosphorylation of PLB.

Phosphorylation state specific binding of AKAP7δ/γ increases phospholamban
phosphorylation
Our finding that the AKAP7δ/γ-PLB interaction is phosphorylation state
specific is interesting given that the purpose of this interaction is to direct PKA
phosphorylation to PLB. Such state selective binding suggests that AKAP7δ/γ
likely binds, phosphorylates, and then unbinds PLB in a dynamic process. Thus
state-selective binding has the potential to increase PLB phosphorylation in
comparison to non-state-specific binding.
To investigate the potential consequence of state specific binding of
AKAP7δ/γ to PLB, we created an ordinary differential equation model that
simulates phosphorylation of PLB by AKAP7δ/γ bound PKA at baseline steady
state and during cAMP stimulation. For all iterations of the model parameters, the
simulation was run for 15000s prior to initiating our stimulation protocol, thus
ensuring that all species reach a baseline steady state. At baseline steady state,
the level of cAMP is 244nm and 2.4% of the total PKA is in an active state.
Following initiation of our stimulation protocol, the levels of cAMP rise to 5.6mM
activating 94.1% of the total PKA in 90s and decaying back to baseline in roughly
500-600s (Figure 3.5A). To test the effect of state specific binding, we compared
the levels of phospho-PLB with either equal affinity of AKAP for PLB and
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Figure 3.5 State dependent binding of AKAP to PLB dramatically increases PLB phosphorylation
upon stimulation. A) cAMP concentration and PKA activity over the time-course of the simulations.
All species in the model are at steady state prior to stimulation (t = 0s), which was achieved via
activation of additional AC. B) pPLB concentration at baseline and maximum following stimulation
for state independent binding of AKAP and PLB. C) pPLB concentration at baseline and
maximum following stimulation for state dependent binding of AKAP and PLB. D) Dynamic range
(𝐷𝑦𝑛𝑎𝑚𝑖𝑐  𝑅𝑎𝑛𝑔𝑒 =   

!"#  !"#$!!"#  !"#$
!"#$%  !"#

) of PLB phosphorylation for both state dependent and

state independent binding of AKAP to PLB. The y-axis is on a log2 scale to enable viewing of both
trends on the same graph.
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phospho-PLB (state-independent), or 1000-fold lower affinity for pPLB (statedependent). We tested AKAP concentrations ranging from 1-250nM for both
state-independent binding and state-dependent binding. Unpublished analysis
from our lab suggests that the level of AKAP7δ/γ present in cardiac myocytes is
roughly 100nm. The total amount of PLB present in these simulations is 50µM
(86). In the range of AKAP concentrations tested, state-independent binding of
AKAP to PLB provides minimal capacity for PLB phosphorylation, with very low
levels of phosphorylation at baseline and minimal response to stimulation (Figure
3.5B). We quantified the response to stimulation by calculating the dynamic
range, defined as the change in concentration of phospho-PLB from baseline to
maximum, divided by the total concentration of PLB. The dynamic range for
state-independent binding ranges from 0.01% to 0.17% (Figure 3.5C). Statedependent binding of AKAP to PLB however, allows for maintenance of low
baseline levels of PLB phosphorylation and dramatic responses to stimulation
(Figure 3.5B). With state-dependent binding, the dynamic range varies from
0.05% to 42.3% (Figure 3.5D). It is important to note that while the primary
determinants of the dynamic range of PLB phosphorylation are the affinity of
AKAP for phospho-PLB and the AKAP concentration, the dynamic range is also
modified significantly by baseline cAMP concentration and the amount of
phosphatase present in the system. Higher baseline concentrations of cAMP
(622nm) contribute to increased baseline activity of PKA and hence higher
concentrations of phospho-PLB (Figures 3.6A and 3.6B). With the same level of
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Figure 3.6 Increased baseline cAMP reduces dynamic range of PLB phosphorylation
A) cAMP concentration and PKA activity over the time-course of the simulations as in figure 5.
The concentrations of AC and PDE have been adjusted to increase the baseline level of cAMP
from 244nm to 622nm. B) pPLB concentration at baseline and maximum following stimulation for
state dependent binding of AKAP and PLB. C) Dynamic range of PLB phosphorylation for state
dependent phosphorylation at low (244nM) and high (622nM) baseline cAMP levels given AKAP
concentrations ranging from 1nM to 250nM. D) Dynamic range of PLB phosphorylation with high
baseline levels of cAMP and normal or increased protein phosphatase (PP).
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stimulation, this results in a decreased dynamic range (Figure 3.6C). Additionally,
it was noted that at higher baseline cAMP concentrations, increasing the AKAP
concentration past 0.15mM resulted in dramatic increases in baseline phosphoPLB. While this threshold effect of AKAP concentration on baseline phospho-PLB
will occur in the simulations with lower baseline cAMP concentrations, it requires
higher concentrations of AKAP than we would expect to see in vivo. We
determined that this is primarily due to a shift in the balance of PKA and
phosphatase activity. Increasing the amount of phosphatase in the simulations
allowed for maintenance of lower baseline phospho-PLB concentrations for
AKAP concentrations at the top of our range, and slightly reduced maximal
phospho-PLB for all AKAP concentrations. This resulted in a reduced dynamic
range at lower AKAP concentrations, yet increased the dynamic range at higher
AKAP concentrations in comparison to simulations with a lower phosphatase
concentration (Figure 3.6D). The model demonstrates that phosphorylation statedependent binding of AKAP7δ/γ to PLB could allow low concentrations of
AKAP7δ/γ to phosphorylate much higher concentrations of PLB. Additionally, the
data suggests that the significant increase in dynamic range seen with statedependent binding is stable over a range of baseline cAMP and phosphatase
concentrations, perhaps allowing for fine-tuning of AKAP7δ/γ complex signaling.
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Discussion
The importance of AKAP7δ/γ to PLB phosphorylation and cardiac calcium
dynamics has recently been called into question by the work of Jones et al (90).
Their AKAP7 PKA binding domain knockout mouse displayed no obvious
phenotype, nor any defect in PLB phosphorylation or Ca2+ handling in response
to sympathetic stimulation.

Hence, the authors suggest that AKAP7 is not

responsible for anchoring PKA to PLB, and suggest that another AKAP likely
performs this function. Their deletion construct is expected to ablate only the
PKA and Cav1.2 binding domains of all AKAP7 isoforms, although no effect on Ltype calcium current was seen.

It is concerning that the authors did not

demonstrate that the truncated protein products do not associate with PKA.
Additionally, it is noteworthy that previous work by this group found that complete
ablation of AKAP5 in mice does not show an obvious phenotype, while specific
ablation of the PKA binding domain does (94). It is possible that deletion of exon
7 behaves more like a full length AKAP7-knockout, which is consistent with the
lack of detection of all isoforms of the AKAP in this model. Additionally, if a
truncated version of AKAP7δ/γ is still expressed in the mouse, it would still bind
all the other components of the complex and perhaps the balance of
phosphorylation to dephosphorylation is changed. Further investigation of this
mouse model is warranted before concluding that AKAP7δ/γ anchoring to PKA is
not important.However, the data shown here clearly demonstrates the role of
AKAP7δ/γ in mediating phosphorylation of PLB. AKAP7δ/γ was first identified as

	
  

76

the AKAP that directs PKA mediated phosphorylation of PLB by Lygren et al in
2007. This work showed that disruption of the AKAP7δ-PKA interaction results in
a reduction in PLB phosphorylation by approximately 50% and that this has a
significant effect on Ca2+ dynamics (27). Our work confirms this finding by
showing that disrupting PKA binding to the complex, or decreasing the affinity for
AKAP7δ/γ and PLB reduces PKA phosphorylation of PLB. Hence, AKAP7δ/γ
should be a key player in the calcium dynamics of the heart.
Several human PLB mutations have been discovered that are associated
with dilated cardiomyopathy. Two PLB mutants in particular, PLB-R9C and PLBΔ14, display hypo-phosphorylation, yet the mechanism of the decrease in
phosphorylation is unclear at present (92, 93). We examined the ability of these
PLB mutants to associate with AKAP7γ and found a significant reduction in PKA
association with the complex and a reduction in phosphorylation of the mutant
proteins when compared to wild-type PLB in cells. Together, these findings
suggest that hypo-phosphorylation associated with the human PLB mutants is
most likely due to impaired interaction with AKAP7δ/γ. Given the clinically
significant phenotype associated with these mutants, our findings indicate that
the AKAP7δ/γ-PLB interaction is critically important for maintaining PLB
phosphorylation and normal cardiac function in humans.
Phosphorylation of PLB by PKA occurs at S16, which is located within the
region of the AKAP7δ/γ binding site. The location of this phosphorylation site
suggests that it may affect AKAP7δ/γ binding to PLB. Our attempts to detect
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AKAP7δ/γ-pPLB binding indicated a lack of association in both transfected cells
and stimulated rat neonatal myocytes. This finding is very interesting, and
suggests that the AKAP7δ/γ-PLB interaction may be very dynamic. Given the
phosphorylation dependence of this binding interaction, AKAP7γ may work by
essentially shuttling PKA from one PLB molecule to the next as it binds, directs
phosphorylation, and then unbinds to find its next unphosphorylated target. This
sort of interaction has the potential to greatly amplify PLB phosphorylation.
To confirm whether the new finding of phosphorylation state binding
dependency on PLB phosphorylation could in fact have such an amplification
effect, we created an ordinary differential equation model of the complex
dynamics.

For

AKAP-PLB

interactions

that

are

phosphorylation

state-

independent, the ability to achieve complete PLB phosphorylation would require
at least an equimolar ratio of AKAP to PLB, since each PLB molecule would need
an associated AKAP-PKA complex. In the range of AKAP concentrations tested,
our model suggests that state-independent binding of AKAP to PLB cannot
achieve levels of PLB phosphorylation that would allow for effective modulation of
SERCA2a activity. Furthermore, the results suggested that state-independent
binding would be insensitive to stimulation given that the dynamic range of
phosphorylation with the maximum amount of AKAP tested is only ~0.2% of the
total PLB concentration. However, state-dependent binding of AKAP to PLB
enables low concentrations of AKAP7γ to direct phosphorylation of much higher
concentrations of PLB. While the concentration of PLB is suggested to be 50µM
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or greater in cardiac myocytes, only 10-20% of the total PLB is in the monomeric
form that can interact with and inhibit SERCA2a (43, 86). Our simulations show
that at physiologically relevant concentrations of AKAP7δ/γ a dynamic range of
PLB phosphorylation can be achieved such that complete phosphorylation of
monomeric PLB is possible. Thus, phosphorylation state-specific binding could
explain the ability of low concentration proteins like AKAP7γ to regulate
phosphorylation of high concentration proteins like PLB and troponin.
Data from our model also highlights the importance of the balance
between AC and PDE activity, as well as PKA and phosphatase activity. The
level of cAMP present in a given AKAP domain clearly defines the maximum
dynamic range possible, as increased baseline cAMP results in higher baseline
PKA activity resulting in a narrowed dynamic range of phosphorylation. While the
increased baseline phosphorylation may be tempered by increased phosphatase
activity, this too results in a slight decrease in the dynamic range of
phosphorylation. Importantly, the significant increase in dynamic range seen with
state-dependent binding, in comparison to state-independent binding, still exists
with variation in baseline cAMP and phosphatase concentration.
This also raises a particularly intriguing hypothesis that such a mechanism
may allow the cell to adapt to fluctuations in baseline cAMP concentration. As
cAMP concentrations rise, additional phosphatase could restore baseline levels
of phosphorylated substrate while still allowing for a sufficient dynamic range to
provide a detectable signal. This important role of phosphatase in the dynamic of
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PLB phosphorylation is consistent with several published results demonstrating
the importance of phosphatase inhibition for PLB phosphorylation, lending further
credence to these findings (95-97).
Our

findings

reaffirm

the

importance

of

AKAP7δ/γ

in

directing

phosphorylation of PLB and present a novel mechanism that can explain the
decrease in PLB phosphorylation associated with human PLB mutants. The
state-dependent binding of AKAP7δ/γ also explains how it may be possible that
low concentrations of AKAP and PKA could regulate phosphorylation of high
concentrations of substrate, as is the case for PLB and troponin. These findings
require us to consider that AKAP complexes in general may be much more
dynamic than previously thought. Further investigation of the AKAP7γ-PLB
complex kinetics is warranted, as well as careful examination of other AKAP
complexes that may also exhibit similar state-dependent interactions.
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Abstract
The second messenger cAMP and its effector cAMP-dependent protein kinase A
(PKA) constitute a ubiquitous cell signaling system. In its inactive state PKA is
composed of two regulatory subunits that dimerize, and two catalytic subunits
that are inhibited by the regulatory subunits. Activation and release of the
catalytic subunits occurs upon binding of two molecules of cAMP to each
regulatory subunit. Although many receptor types existing within the same cell
may use this signaling system, compartmentation of signaling does occur due to
A-Kinase Anchoring Proteins (AKAPs), which act to co-localize PKA with specific
substrates. The molecular mechanism allowing AKAPs to direct PKA
phosphorylation to a particular substrate remains unknown. This is primarily due
to the large body of evidence suggesting that the catalytic subunit, which is highly
diffusable, is released in response to cAMP. Recent evidence from Smith et al
suggests that in the cell, the catalytic subunit may not be released from the AKAP
complex (52). They further demonstrated that alterations in the structure of the
PKA regulatory subunit tether affect substrate phosphorylation. We use novel
computational software based on Langevin dynamics, Langdyn, to simulate the
AKAP-PKA complex in order to determine a molecular mechanism for the
changes in phosphorylation seen with alteration in tether length and flexibility,
and also to demonstrate whether or not AKAPs can effectively direct PKA
phosphorylation to a particular substrate upon release of the catalytic subunit
from the complex. We find that short and flexible tethers contribute to a decrease
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in the average characteristic time of binding, allowing the catalytic subunit to
spend more time in a bound state with the substrate, which yields faster
characteristic times of phosphorylation. We further demonstrate that release of
the catalytic subunit from the AKAP complex abrogates the effect of tethering,
with characteristic times of phosphorylation similar to non-AKAP bound PKA. The
data demonstrates that AKAPs likely do not release the catalytic subunit in
directing PKA phosphorylation to AKAP bound substrates. In combination with
the changes in characteristic time of phosphorylation that are driven by tether
structure, this work indicates that the purpose of AKAPs may be to increase the
efficiency of phosphorylation of particular AKAP substrates.
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Introduction
The second messenger cAMP and its effector, cAMP-dependent protein
kinase A (PKA), constitute a ubiquitous cell-signaling network responsible for the
phosphorylation of numerous substrates. Recent experimental methods that
employ mass spectrometry identify 112 potential PKA substrates in a single cell
type (5). The existence of such an abundance of PKA substrates in a single cell
highlights the importance of signal compartmentation within the cAMP-PKA
signaling pathways. Achieving phosphorylation of specific substrates in response
to an extracellular stimulus is complicated by the rapid diffusion of cAMP and
also by diffusion of the PKA catalytic subunit. The vast majority of evidence
regarding PKA activation indicates that binding of cAMP to allosteric sites on the
regulatory subunits results in the simultaneous activation and release of the
catalytic subunit (10). The co-discoverer of cAMP, Ted Rall, once said that this
scheme presents “…the unsatisfying picture of the catalytic subunit of protein
kinase swimming about, happily phosphorylating a variety of cellular constituents
whether they need it or not”(98).
However, it is clear that there is great specificity in PKA phosphorylation
dynamics. It has been known since the late 1970’s that cAMP-PKA signaling is
actually compartmentalized. Stimulation of the β-adrenergic receptor in
cardiomyocytes was shown to the activate glycogen phosphorylase, while
stimulation of the PGE1 receptor did not, even though both receptors signal via
cAMP and PKA (8). The discovery of A Kinase Anchoring Proteins (AKAPs) has
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provided at least a partial explanation of signal compartmentation. This class of
proteins coordinates a multi-protein signaling microdomain by co-localizing PKA
with specific substrates and additional effectors like phosphodiesterase,
adenylate cyclase, and phosphatase (29). The ability of an AKAP to coordinate
such a multi-protein signal complex allows for the local production and
degradation of cAMP, thereby spatially restricting PKA activation. Co-localization
of PKA with its substrates in this manner is hypothesized to confer specificity of
phosphorylation by increasing the local concentration of PKA. While achieving a
high local concentration of PKA via anchoring to a specific substrate in a
particular location is straightforward, the result of this mechanism following PKA
activation and release is less obvious. Since the activated catalytic subunit is
freely diffusible, it may diffuse to and phosphorylate other substrates in the same
manner expected for the AKAP bound substrate. While phosphorylation of nonlocal substrates may be inhibited by the presence of protein kinase inhibitor (PKI),
a pseudosubstrate inhibitor of PKA, it must be acknowledged that PKA will not
necessarily diffuse to and phosphorylate its associated substrate even if released
in close proximity of its substrate.

Thus, these data call into question the

mechanism of PKA scaffolding.
In contrast, recent evidence has surfaced that PKA is not released
following stimulation and is able to maintain catalytic activity while bound to its
regulatory subunit (50, 52). The ability of PKA to phosphorylate its substrates
while remaining bound to the AKAP complex would provide for a much more
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convincing hypothesis regarding specificity of substrate phosphorylation. This
novel mechanism of PKA activation has recently been investigated by cryo-EM
using AKAP7γ as a model system.

The AKAP7γ-PKA complex has been

demonstrated to posses a remarkable amount of conformational flexibility owing
to the intrinsically disordered tether region of the PKA regulatory subunits (52).
This tether restricts the catalytic subunit to space within ~16nm of the AKAP-PKA
interface.

Truncation

of

the tether

was

shown

to increase substrate

phosphorylation relative to phosphorylation with the WT tether length. It was
further demonstrated that following stimulation with the β-adrenergic agonist
isoproterenol, the catalytic subunit remains within the AKAP complex. These
results suggest that the tether physically constrains PKA to the location of the
substrate during phosphorylation and that the structure of the tether is an
important determinant of substrate phosphorylation. Importantly, these findings
suggest that scaffolding of PKA to substrates by AKAP may not function as
currently hypothesized.
Using a computational approach, we sought to provide a mechanistic
explanation for the results of Smith et al by determining how tether length and
flexibility are able to affect phosphorylation. Additionally, we aimed to investigate
the effect of releasing the catalytic subunit on the rate of substrate
phosphorylation in order to demonstrate whether or not the current hypothesis
regarding AKAP function is reasonable. We used Langevin Dynamic (LD)
simulation to explore the effect modulating the length and flexibility of the PKA
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tether region on phosphorylation of AKAP complex bound substrate. Our work
demonstrates that shorter and more flexible tethers allow the catalytic subunit to
interact with its substrate more often, resulting in higher rates of phosphorylation.
Furthermore, our simulations of catalytic release from the AKAP complex
demonstrate that anchoring PKA to its substrate does not reliably direct the
catalytic subunit to substrates within the complex if it is released from the
complex. This suggests that to obtain the substrate specificity seen in multiple
experimental models, PKA must retain its holoenzyme conformation.

Our

findings strongly support emerging evidence that the PKA catalytic subunit is
retained within the AKAP-PKA complex. Interestingly, the same mechanism that
explains substrate specificity of the AKAP complex also seems to confer high
catalytic efficiency, helping to explain the observation that AKAPs increase the
speed of substrate phosphorylation (26). This work lends new meaning to the
idea of local concentration that better explains the ability of AKAPs to control
substrate specificity.
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Methods
Langevin Dynamic Modeling
LD simulations were carried out using Langdyn, novel software written by Dr.
Paul Michalski. Langdyn is an appropriate modeling platform when the molecules
in the system can be described in a coarse-grained manner as a set of
biochemically distinct spherical sites connected by stiff links. The AKAP-PKA
complex is well described in this manner. Models that seek to describe finer
details, such as the motion of individual amino acids, are more appropriately
simulated with molecular dynamics, while models with less detail will run faster
with other solvers.
Molecules are constructed in the graphic user interface in a three-step
process. First, the types of sites in the molecule are defined. For the AKAP-PKA
complex, there are five types of sites: an anchor, which is necessary for linking
molecules to a membrane, substrate, AKAP_R (AKAP bound to the regulatory
subunit dimer), R_C (regulatory subunit bound to the catalytic subunit), and flex
links that allow us to modulate flexibility of the regulatory subunit tether. Each
type can possess an arbitrary number of internal states, which can be associated
with a set of biochemical reactions (reactions are described below). For example,
substrate is assigned two states, unphosphorylated and phosphorylated. Each
type also has an associated physical size, diffusion constant, and color (for
visualization purposes).
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Secondly, sites are added to the molecule, and each site is assigned one
of the previously defined types. To construct the AKAP-PKA complex we add a
minimum of seven sites: an anchor, substrate, AKAP_R, two flex links, and two
R_C. Physically, sites are modeled as impenetrable spheres in order to
accurately capture excluded volume effects.
Lastly, links are added to connect the sites to each other. Each site can be
linked to an arbitrary number of other sites in either two or three-dimensions. The
only requirement is that sites cannot overlap. Links are stiff and thus define an
inter-site distance, but are free to rotate around the sites. For example, a
triangular molecule with three sites will not maintain its geometry in the simulation
with only two links, but will if a third bond is added to enforce a distance between
the two outer sites. Links are only used to control the distance between sites and
do not occupy physical space, and both sites and other links are free to pass
through a link. Excluded volume is only enforced by sites.

Geometry
Langdyn currently only supports a rectangular geometry with reflecting
boundary conditions. The rectangular geometry is partitioned into an extracellular space, a planar membrane, and an intracellular space. The size of the
membrane and the depths of the intra- and extra-cellular spaces are user defined.
Future versions of Langdyn will support a wider variety of geometries.
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Particle Motion: Diffusion and Constraints Due to Binding
Particle motion is influenced by two classes of forces: random forces that
lead to diffusional motion, and inter-particle forces that impose the constraints
from intra- and inter-molecular bonds. These forces are incorporated in the overdamped Langevin equation (1) (99),
1         𝜁𝑣 = 𝐹rand + 𝐹bonds
where 𝜁 is the coefficient of viscous friction, 𝑣 is the particle velocity, and 𝐹rand
and 𝐹bonds represent the random forces and the total force of bonds. The random
forces are guaranteed to recapitulate the desired diffusion provided they are
chosen from normal distribution with variance
2        𝐹rand (𝑡) ∙ 𝐹rand (𝑡′) = 2𝑛𝑑 𝐷𝜁2   𝛿(𝑡 − 𝑡′ )
where D is the desired diffusion coefficient, 𝑛! is the dimension of the system
(here 𝑛! = 3), and the delta function simply states that the random force is
uncorrelated in time. The bonds are modeled as stiff springs,
3       𝐹bonds =

𝑘𝑖    𝑟𝑖 − 𝑟0,𝑖   𝑟𝑖
𝑖

where the sum runs over all bonds, 𝑘! is a spring constant, 𝑟! is the unit vector
pointing from the particle to the neighbor with which it shares a bond, 𝑟! is the
current inter-particle distance, and 𝑟!,! is the equilibrium bond distance. The exact
value of the spring constant is not important, provided the spring is stiff enough to
keep sites near the expected distances but not so stiff that accurate motion
requires unreasonably small time steps. In Langdyn all bonds have a spring
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constant that allows us to use time steps on the order of 1 to 100 ns for
biologically relevant diffusion constants.

Reactions
Zeroeth-order. Langdyn supports particle creation reactions, which are
often used to buffer the concentration of a species. Given a macroscopic creation
rate, 𝑘create , with units µM/s, a single molecule is added to the system at each
time step with probability 𝑘create 𝑉𝑑𝑡, where 𝑉 is either the intra- or extra-cellular
volume depending on the location of the molecule.
First-order. Langdyn supports two general types of first order reactions,
both of which are described by a reaction rate, 𝑟, with units s-1, and which occur
at each time step with probability 𝑟𝑑𝑡. These are: 1) Bond dissociation reactions.
When a dissociation reaction occurs the bond is simply removed from the system.
2) Internal state transitions. These describe the transitions between the internal
states of each site, as defined by the type of that site. The probability of these
transitions can depend on the identities of binding partners or the states of other
sites in the same molecule. The former dependency would be used to prevent a
transition from an unphosphorylated to a phosphorylated state unless the site is
bound to a kinase. The latter dependency can be used to model allosteric
interactions.
Second-order. Langdyn supports binding reactions between two sites. A
bond is modeled by the creation of a new link between the reacting sites. The link

	
  

91

modeled identically to the links which hold molecules together, except it has an
associated off rate which controls molecular dissociation. Particle-based
simulations often use the Smoluchowski approach (100) to model bimolecular
reactions, but such an approach is incompatible with excluded volume. Instead,
we modified the approach described in Ref. (101) to account for excluded volume.
Each site is associated with two radii, the physical radius, 𝜌! (i=1,2), which is
defined in molecule construction and enforces excluded volume, and a slightly
larger reaction radius, 𝑅! . Two reactive sites undergo a binding reaction with
probability 𝜆  𝑑𝑡 per time step when their reaction radii overlap. The reaction rate 𝜆
is related to the macroscopic on rate, 𝑘on , with units of 𝜇𝑀!! 𝑠 !! , through
4         𝑘on = 4𝜋𝑅𝐷 1 −
where 𝑟! =

𝑟! 𝜌 cosh 𝑅 − 𝜌 /𝑟! +    𝑟! sinh 𝑅 − 𝜌 /𝑟!   
𝑅   𝑟! cosh 𝑅 − 𝜌 /𝑟! +   𝜌 sinh 𝑅 − 𝜌 /𝑟!

𝐷/𝜆, 𝐷 = 𝐷! + 𝐷! , 𝜌 = 𝜌! + 𝜌! , and 𝑅 = 𝑅! + 𝑅! .

The AKAP-PKA complex model consisted of a single molecule composed of five
types with a structure based on the published geometry of the complex as
detailed in the results (52). For each model variant, a 1sec simulation of a single
complex in a 50nm3 volume was run 500 times on a high performance computing
cluster. The phosphorylation state of the complex was recorded at 10ms intervals
yielding 100 data points per simulation.
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Data reduction and analysis
Data reduction and analysis was performed using custom scripts written in
Python using the SciPy library. To determine the characteristic time of binding or
phosphorylation, 500 runs of a single model were grouped into sets of 50 runs
and the average for the unbound or unphosphorylated state was taken at each
time point. Since there is only 1 molecule per simulation, this produces an
exponential decay from 1 to 0 as the average state of the molecule transitions
from completely unbound or unphosphorylated to completely bound or
phosphorylated. The resulting 10 sets of averaged data produced from the 500
runs were then fit with a single exponential model (Eq. 5), where y is the average
value of the state, b is the inverse of the characteristic time of binding or
phosphorylation, and t is time.
5   𝑦 = 𝑒 !!∗!
The mean and standard deviation of the characteristic times for the 10 sets of
averaged data are reported.
To determine the average time spent in the bound state for a given set of
simulations, the total number of data points in which the complex existed in a
bound state was determined for each run. The time spent in the bound state was
then averaged for all 500 simulations of a particular model. The mean and
standard deviation are reported for each model variation.
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Analytical Prediction of Phosphorylation Rate
Expected catalytic rates for PKA were calculated using the standard
Michaelis-Menten equation (Eq. 6), where V is reaction velocity (mm/s), kcat is the
catalytic rate (s-1), Km is the Michaelis constant (mM), and [E] and [S] are the
enzyme and substrate concentrations (mM) respectively.
6   𝑉 =   

𝑘!"# 𝐸 [𝑆]
𝐾𝑚 + [𝑆]

This model of ensemble enzymatic reactions has been shown, both theoretically
and experimentally, to hold for single molecule reactions (102, 103). The
Michaelis constant was calculated from the following equation (Eq. 7), where kcat
is the catalytic rate and kf and kr are the reverse and forward rate constants for
the binding of enzyme to substrate.
7   𝐾𝑚 =   

𝑘! + 𝑘!"#
𝑘!

Since the volume accessible to the catalytic subunit is limited by the tether length
(distance from center of the AKAP_R subunit to center of RC), the concentrations
of E and S were adjusted to a spherical volume with a radius equal to the tether
length. Given the adjusted concentrations and known kcat, kf and kr, we determine
V (µM/s). The reaction velocity is then converted to catalytic rate by dividing
through by the adjusted enzyme concentration.
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Results
Modeling the AKAP-PKA complex
Simulation of substrate phosphorylation within the AKAP-PKA complex is
a multifaceted task that necessitates accounting for structural details in addition
to standard reaction kinetics. Such structural detail generally falls within the realm
of molecular dynamics simulation; however, this method is very computationally
expensive and would not be appropriate given the time-scales of the binding and
phosphorylation reactions in question. Similarly, stochastic simulation of this
reaction network could be accomplished using a tool like Smoldyn. Yet, this
method does not account for space filling of molecules and the spatial resolution
of this type of modeling would be pushed to its absolute limits. Our novel
simulation software takes advantage of Langevin Dynamics (LD) to provide a
meso-scale modeling platform that accounts for coarse-grained structural details
and is capable of simulating the AKAP-PKA complex with the appropriate spatial
resolution.
In the LD software, molecules are constructed from spheres or sites of a
particular type and springs or links. Our model of the AKAP-PKA complex is
constructed of 5 molecular types: anchor, substrate, AKAP_R, linker, and RC
(Fig 4.1A). The geometry of the AKAP complex is based upon the 3D
reconstruction from Smith et al (52). In order to link the molecule to the
membrane it is necessary to include an anchor, which represents the membrane
insertion of our target substrate. The interface of AKAP with the
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Figure 4.1 Langevin Dynamic Model of the AKAP-PKA complex. A) Structure of the AKAP-PKA
complex with labeled site types. B) A total of 190 model variants were created that vary in both
flexibility (left) and length (right). C) Model Parameters. Characteristics assigned to each site type
(above) and kinetic parameters of each reaction network (below).
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dimerization/docking domain of the PKA regulatory subunits is represented by
AKAP_R, and the catalytic subunit bound to the inhibitory domain of the
regulatory subunit is represented by RC. The diffusion rates of the molecule
types are based upon standard rates for cytosolic and membrane bound proteins.
The diffusion rate of GFP in chinese hamster ovary cells has been measured at
27µm2/s (104). Although our diffusion coefficient for RC is roughly one order of
magnitude less than that of GFP, simulations with diffusion coefficients varying
from 3-15µm2/s show no effect on the characteristic time of phosphorylation (data
not shown). Diffusion rates for transmembrane proteins are generally less than
0.1µm2/s. Since links between sites are stiff, we create flexibility in the link
between AKAP_R and RC by adding dummy sites called flex links. By increasing
the number of links in the tether, we are able to increase the flexibility. To
simulate the effects of tether length and flexibility on the rate of substrate
phosphorylation, we created a series of models in which the total length of the
tether (center of AKAP_R to center of RC) is varied as well as the number of link
segments (Fig 4.1B). A total of 190 model variations were created with lengths
varying by increments of 1nm from 9.25m to 25.25nm, and flexibility ranging from
a minimum of 2 link segments to a maximum of 14 link segments. For shorter
tether lengths, the maximum number of link segments is limited by the number of
flex link sites that could be fit within the tether length. The properties assigned to
each site type as well as the kinetics of the simulated reactions are outlined in
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figure 4.1C. The reaction kinetics are based on electronic measurements of
single-molecules catalysis by PKA (105).

AKAP-PKA complexes with shorter more flexible tethers display faster
characteristic times of enzyme-substrate binding and spend more time in the
bound state on average
Phosphorylation of substrates by PKA occurs in a multi-step process
involving binding of both ATP and substrate prior to catalysis. Due to the high
cellular concentration of ATP, it is reasonable to model this process in two steps:
1) binding of PKA and substrate, 2) phosphorylation of substrate. Given that the
catalytic rate of PKA is unlikely to be altered by the structure of the tether, we
hypothesized the any changes in the apparent rate of catalysis would be driven
by altered binding of the catalytic subunit with its substrate.
We first examined the characteristic time of binding (CTB), defined as the
time from simulation start to the first binding event (Fig 4.2A). For this set of
simulations, only the forward binding reaction was included (Fig 4.1C). CTBs
varied from a minimum of 0.445ms ±0.078 to a maximum of 3.812ms ± 0.563. In
general, shorter and more flexible tether lengths displayed faster CTBs. The
effect of varying tether length is most dramatic for the least flexible model
variations, while there is virtually no difference in the CTB with change in length
for the most flexible model variations. Similar trends are seen with changes in
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flexibility at the extremes of the model variations. Changes in tether flexibility
affect CTB least for short tether lengths and most for longer tether lengths.
Since the catalytic rate of PKA (21s-1) is much slower than kr for binding of
catalytic to substrate (350s-1), binding and unbinding of the catalytic subunit and
substrate is expected to occur multiple times prior to phosphorylation on average.
Model variations allowing catalytic and substrate to exist in a bound state for a
greater fraction of total simulation time were hypothesized to have an increased
probability of substrate phosphorylation and hence faster characteristic times of
phosphorylation (CTP). We determined the average fraction of time spent in the
bound state (FTB) by simulating binding and unbinding of catalytic subunit and
substrate without allowing substrate phosphorylation (Fig 4.1C). The average
FTB ranged from 0.415 ±0.05 to 0.847 ±0.043 with variations following the same
trends as for characteristic times of binding (Fig 4.2B). Since the kf and kr remain
unchanged for all model variations, the differences in the FTB must result from a
change in the apparent forward rate of binding.
Increases in apparent kf of binding and average time spent in the bound state
translate to decreases in characteristic times of phosphorylation
The variation in the CTBs and FTBs suggested that changes in the tether
length and flexibility were likely to affect substrate phosphorylation. Model
variations displaying an increased FTB were expected to display shorter CTPs
because this should increase the probability of phosphorylation. We determined
the CTP by simulating binding and unbinding of the catalytic subunit to substrate,
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Figure 4.2 Tether length and flexibility modulate binding of the catalytic subunit to substrate. A)
Characteristic times of binding with varied tether length and flexibility. Simulations were run for
only the binding reaction of catalytic and substrate (no unbinding). Each data point represents the
average time from simulation start to binding of catalytic and substrate for 10 sets of 50
simulations ±1SD. B) Average fraction of time that the catalytic subunit and substrate spend in the
bound state. Binding and unbinding of the catalytic subunit with substrate were simulated over the
course of 1s. Each data point represents the average fraction of time(s) ±1SD for 500 simulation
runs.
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and irreversible substrate phosphorylation (Fig 4.1C). CTPs varied from a
minimum of 0.054s ±0.004 to a maximum of 0.119s ±0.012 (Fig 4.3A). As
expected, the general trend was that models with shorter and more flexible
tethers to displayed the fastest CTPs.
In order to verify that the CTPs predicted from the LD simulations are
realistic, we used the quasi-steady state Michaelis-Menten model of enzyme
kinetics to generate an analytical prediction for comparison. While the
assumptions implicit in the original derivation of Michaelis-Menten kinetics are not
valid for our single molecule simulations, it has been demonstrated both
theoretically and experimentally that this model is a good approximation of
reaction velocity even for single enzyme kinetics (102, 103). In order to determine
the expected CTP using the Michaelis-Menten model, we adjusted the
concentrations of the catalytic subunit and substrate by considering their local
concentrations to be the number of molecules within a spherical volume having a
radius equal to the length of the tether. The predicted reaction velocity was then
converted to a catalytic rate (inverse of CTP) by dividing by the local
concentration of the catalytic subunit. The analytical predictions of CTP agree
reasonably well with the LD simulation results for models with the most flexible
tethers for each length (Fig 4.3B). The characteristic times of phosphorylation
predicted by Michaelis-Menten kinetics are roughly twice as fast as those
predicted by LD simulation. This deviation from the analytical prediction is a
result of anchoring of the substrate to the membrane, which prevents its free
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Figure 4.3 Tether length and flexibility modulate the rate substrate phosphorylation. A)
Characteristic times of phosphorylation with varied tether length and flexibility. Simulations
included binding and unbinding of the catalytic subunit with substrate as well as irreversible
substrate phosphorylation. Each data point represents the average time from simulation start
phosphorylation of substrate for 10 sets of 50 simulations ±1SD. B) Comparison of characteristic
times of phosphorylation for the most flexible model variations at each length to characteristic
times of phosphorylation predicted by Michaelis-Menten kinetics with adjusted concentrations of
enzyme and substrate. A second set of LD simulations of the most flexible tether variations with
only one catalytic subunit was run for each length for comparison to the analytical predictions.
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diffusion within the same volume occupied by the catalytic subunits thereby
reducing the CTP.

Release of the catalytic subunit abrogates the effect of PKA tethering for a single
AKAP-PKA-substrate complex
It is well established that the primary function of AKAPs is to
compartmentalize cAMP/PKA signaling. Numerous studies have demonstrated
that disruption of AKAP binding to a particular substrate leads to a decrease in
phosphorylation or change in the expected physiologic response (23, 24, 35).
How AKAPs direct PKA phosphorylation to AKAP complex bound substrates
remains unknown as the widely accepted mechanism of signaling requires the
release of the catalytic subunit (10). In light of our findings that the structure of
the regulatory subunit tether alters phosphorylation kinetics and evidence that the
catalytic subunit is not released from the AKAP-PKA complex, we simulated the
release of the catalytic subunit from the complex to determine its effect on
substrate phosphorylation.
To simulate the effect of releasing of the catalytic subunit on
phosphorylation of AKAP complex bound substrate, we removed the tether from
the model and initialized the simulations with two catalytic subunits positioned
within 16.25nm of AKAP_R (WT), within 5nm of the substrate (close), or
randomly throughout the 50nm3 simulation space (Fig 4.4A). Positioning of the
catalytic subunits at the maximum distance from AKAP_R that could be expected
for the wild type geometry lead to an average CTP of 0.193s ±0.025. Interestingly,
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Figure 4.4 Simulation of release of the catalytic subunit from the AKAP-PKA complex. A)
Release of the catalytic subunit was simulated by removing the tether from the model and
initializing the simulations with the catalytic subunits positioned either 16.25nm from substrate,
5nm from substrate or randomly within the simulation space. The characteristic times of
phosphorylation are compared to the analytical prediction for two catalytic subunits and a single
3
substrate within a 50nm volume. B) Predicted change in characteristic time of phosphorylation
(CTP) and mean squared distance of PKA as two catalytic subunits diffuse from their initial
position within the AKAP complex.
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positioning the catalytic subunits close enough to the substrate for binding to
occur in the first time step of the simulation did not improve the CTP (0.208s
±0.031). Positioning the catalytic subunits within the space available to tethered
PKA also did not improve the CTP compared to random positioning of the two
catalytic subunits within the simulation space (0.210s ±0.026). These results
suggest that anchoring of PKA to substrates by AKAP is not an effective method
of directing PKA phosphorylation to the bound substrate if the catalytic subunit
must be released in order for phosphorylation to occur. Regardless of how close
the catalytic subunits are positioned upon release, the CTP does not differ from
that of randomly placed catalytic subunits. Once released, the CTP is equal to
the expected CTP for catalytic subunits with access to the entire compartment
that it is located in. Even for the very small volume of our simulation space, the
CTPs for catalytic release are much slower than the rates for all tether models
with the WT length (min 0.059s ±0.007 to max 0.087s ±0.011).
For

some

cell

types,

like

the

cardiac

myocyte,

AKAP

directs

phosphorylation to substrates that are distributed throughout the cytosol, thus the
released catalytic subunit is not confined to a small compartment as in our LD
simulations. In this case, the CTP for the substrate that the catalytic subunits
were initially tethered to would decrease rapidly due to diffusion away from the
initial location. Using our Michaelis-Menten analytical method, we predicted the
change in the CTP over time as the catalytic subunits diffuse away from their
initial position (Fig 4.4B). The change in concentration of catalytic subunit over
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time was determined for a spherical volume with a radius equal to the mean
squared displacement (MSD) of the catalytic subunit (Eq. 8).
8   𝑀𝑆𝐷 =    6𝐷𝑡
Once released, the catalytic subunit quickly diffuses away resulting in a drastic
increase in the CTP (Fig 4.4B). The increase in CTP is such that after a few ms it
would be unreasonable to expect that the catalytic subunit would return to its
initial location and phosphorylate the AKAP bound substrate. Importantly, this
demonstrates that outside of a small compartment like the dendrite of a neuron,
release of the catalytic subunits from the AKAP-complex would be even less
effective at achieving phosphorylation of complex bound substrates than for our
small volume LD simulations.

Discussion
The importance of AKAPs in compartmentalization of cAMP-PKA signaling
has been well demonstrated (23, 24, 35). It is now widely accepted that AKAPs
not only tether PKA to a particular substrate, they also co-localize with other
signal effectors like adenylate cyclase and phosphodiesterase, thereby acting to
coordinate a signaling microdomain (29). Even though great progress has been
made in our understanding of the spatial coordination of signaling components by
AKAPs, how these AKAP complexes operate at the single molecule level
remains poorly understood. While AKAPs are named for their ability to direct PKA
phosphorylation to a particular substrate, we still do not have a molecular
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mechanism to explain how this occurs. This phenomenon is further complicated
by years of evidence suggesting that activation of PKA requires the release of a
freely diffusible catalytic subunit. However, recent evidence suggests that in the
cell, the catalytic subunit is capable of phosphorylating AKAP complex bound
substrates without being released (50, 52). It has been further demonstrated that
structure of the PKA regulatory subunit tether is an important determinant of
substrate phosphorylation.
We used Langevin Dynamic simulation of the AKAP-PKA complex to
further explore the contribution of the structure of the PKA regulatory subunit
tether to substrate phosphorylation with the hope of gaining additional
mechanistic insight into the function of the AKAP-PKA complex. Our work first
demonstrates that modulation of the tether length and flexibility changes the CTB
between the catalytic subunit and substrate, with shorter and more flexible
tethers tending to have faster CTBs (Fig 4.2A). The change in CTB, resulting only
from alterations in tether structure, modulates the fraction of time that catalytic
subunit and substrate spend in a bound state (Fig 4.2B). This translates into
changes in the CTP, with models having higher FTBs showing decreased CTPs
(Fig 4.3A). Since our primary interest is to understand how AKAPs direct PKA
phosphorylation to AKAP bound substrates we also simulated how the release of
the catalytic subunit from the complex affects phosphorylation. Positioning of the
catalytic subunits within the space available to the WT tether length does not
result in CTPs that are significantly different from those positioned randomly
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throughout the simulation space, indicating that AKAPs do not effectively direct
PKA phosphorylation to AKAP bound substrates if the catalytic subunits are
released (Fig 4.4A). We further demonstrate that in a large compartment like the
cytosol, release of the catalytic subunit from the AKAP complex would lead to its
quick diffusion away from the anchored substrate without phosphorylation (Fig
4.4B). The results of our simulations suggest that in the cell the catalytic subunit
is likely not released, as this would lead to a significant decrease in the efficiency
of phosphorylation of AKAP complex bound substrates.
The decreased CTB and increased FTB for shorter tether lengths reflect
an increased apparent forward rate of binding. Since the rate constants (kf and kr)
remain the same for all model variations, the changes in the apparent forward
rate indicate that the structure of the tether influences the probability of
interaction of the catalytic subunit with its substrate. As the regulatory subunit
tether is shortened, the space available to the catalytic subunit decreases,
thereby increasing the probability that it will encounter and bind to the substrate
as long as the substrate remains accessible. The increased probability of
interaction has previously been interpreted as resulting from an increase in the
local concentration of the catalytic subunit. While this interpretation allows us to
easily predict the CTP via the Michaelis-Menten model, the changes in CTB, FTB,
and CTP result from differences in structure, not concentration, and thus are
more correctly thought of as changes in apparent forward rate constant. The
flexibility of the tether likely modulates accessibility of the space within the
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spherical volume defined by the tether length. For lengths that allow access to
substrate in the most extended conformation, flexibility has little impact on CTB
or FTB. With longer tethers that must deform in order to reach the substrate,
changes in flexibility have much more impact on the CTB and FTB (Fig 4.2).
Although differences in the regulatory subunit tether length are only expected
with interspecies variation, positioning of substrates within the AKAP complex
does vary and would affect rates of interaction similarly. One potential caveat to
bear in mind is our inability to account for rotational conformation. In reality,
phosphorylation of substrates by the catalytic subunit would require precise
alignment of the catalytic cleft with the substrate. It may be possible that a certain
degree of tether stiffness could actually facilitate phosphorylation by maintaining
proper alignment of the catalytic subunit and substrate.
Changes in the CTP with tether length and flexibility are most likely driven
by changes in the apparent forward rate of binding. Although the idea of a local
concentration offers a simple method for analytical prediction of the CTP, the
actual concentration of the catalytic subunit and substrate do not change.
Considering the changes CTB and FTB as resulting from changes in apparent kf
rather than concentration offers interesting insight into the changes in CTP and,
more generally, the function of AKAPs. Increasing the kf of the binding reaction
results in a decrease in the Michaelis constant (Methods Eq. 7), which translates
into an increase in the velocity of the phosphorylation reaction according the
Michaelis-Menten model (Methods Eq. 6). Interestingly, such change in the Km
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also suggests that the efficiency of phosphorylation is improved according to the
following equation (Eq. 9), where E is catalytic efficiency:
9   𝐸 =

𝑘!"#
𝐾𝑚

This interpretation of the change in CTP resulting from changes in tether
structure is a previously unconsidered, but incredibly important advancement in
our understanding of the function of AKAPs. It suggests that AKAPs don’t simply
increase the speed or magnitude of phosphorylation by increasing local
concentration of PKA, rather AKAPs increase the efficiency of phosphorylation of
the AKAP complex bound substrate.
The increase in efficiency of phosphorylation of AKAP bound substrates is
best illustrated by comparing the CTPs of tether models with those from our
models of catalytic release. For models involving catalytic release, the CTP is at
minimum 2.5-fold slower than the slowest tether model. Given the small size of
our simulation space and our evidence that the rate of substrate phosphorylation
depends on the size of the compartment for free catalytic subunit, the increase
CTP is likely to be much more dramatic for most AKAP-PKA signaling systems in
the cell.
Our new hypothesis regarding the function of AKAPs also offers some
interesting interpretations of old data. While the definition of local concentration of
PKA in the previous hypothesis is somewhat ambiguous, we will define it as
concentration of PKA within the compartment of the AKAP-PKA complex.
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Experiments in which AKAP-substrate binding has been disrupted demonstrate a
reduction in phosphorylation of the intended substrates (24, 27). While this was
attributed to de-localization of PKA and hence, a decrease in local concentration,
our evidence indicates that such delocalization would also occur upon activation
of PKA if the catalytic subunit is released from the complex in order for
phosphorylation to occur. The effect of tethering the catalytic subunit to its target
is even better demonstrated through the use of the FRET sensor AKAR (A
Kinase Activity Reporter 2), which measures PKA phosphorylation real time in
cells (25). Addition of the PKA binding site to the AKAR2 construct resulted in
FRET signal changes following stimulation that were both faster and of higher
magnitude when compared to AKAR2 alone (26). Since AKAR2 with or without
the addition of the PKA binding site is localized only to the cytosol, it is not
reasonable to assert that there is difference in the local concentration of PKA.
The sensor is located in the same compartment in both cases and we are not
forcing redistribution of PKA to a larger space by preventing AKAP localization to
a particular substrate. Our hypothesis that AKAPs increase the efficiency of
AKAP complex bound substrate phosphorylation fits very well with this data. Our
simulation data suggests that the increased rate of phosphorylation, and likely
the increased magnitude, is what should be expected. Interestingly, we find that
the kinetics of phosphorylation for released catalytic subunit are too slow to
mediate some signal processes known to require PKA. The time scale of PKA
mediated effects on Na2+ channels occur on the order of milliseconds, which
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according to our LD simulations occurs too quickly to be mediated by the catalytic
subunit if released from the complex (36).
Computational analysis of the AKAP-PKA complex using our novel
software, Langdyn, has led to numerous exciting findings. First, we offer a
mechanism for the changes in phosphorylation rate seen with alteration in the
structure in regulatory subunit tether. Second, we present evidence that release
of the catalytic subunit would likely abrogate the effect of tethering PKA to a
particular substrate. This evidence suggests that for efficient substrate
phosphorylation to occur, the catalytic subunit cannot be released. This change
in the mechanism of phosphorylation also provides us with a partial molecular
mechanism that explains how AKAPs might direct PKA phosphorylation to AKAP
complex bound substrates. Finally, we propose an improvement to the
hypothesis that AKAPs increase the speed and magnitude of substrate
phosphorylation by increasing local concentration. We hypothesize that AKAPs
act to increase the efficiency of PKA phosphorylation and suggest that local
concentration should be thought of as the amount of enzyme and substrate within
a volume defined by the length of the regulatory subunit tether, rather than within
a local region or compartment within the cell. This revision of the AKAP
hypothesis represents a critically important step forward in our understanding of
PKA signaling.
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Chapter 5
Conclusions
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Since its discovery in 1958 by Sutherland and Rall, much progress has
been made in our understanding of cAMP signaling. We know that cAMP is
produced by adenylate cyclase (AC) following activation of G-protein coupled
receptors (GPCRs) at the cell surface, that the rise in cAMP concentration
activates signal effector proteins like PKA, exchange protein directly activated by
cAMP (Epac), and cyclic nucleotide-gated channels, and that this signal is
terminated by phosphodiesterases (PDEs) that degrade cAMP. It is understood
that although many different GPCRs use cAMP and PKA to convey their signals,
this signaling system is compartmentalized primarily through the ability of Akinase anchoring proteins (AKAPs) to tether PKA to a particular substrate, thus
directing its phosphorylation to the intended downstream target (106). We have
also discovered that many AKAPs are capable of binding to AC, PDE, and other
signal effectors, thereby allowing AKAPs to coordinate a cAMP-PKA signaling
microdomain in which all of the necessary components are co-localized (29).
Much of the work that has been done up to this point has focused upon
identifying components of the AKAP complex and examining changes in
physiology when specific components are inhibited or prevented from associating
with the complex. This has lead us to think of the AKAP complex as a static entity
in which all of the components necessary for signaling are always present in the
complex, or at least in a vaguely defined compartment of the target substrate.
The work presented here forces us to think of the AKAP complex in new
ways that represent an evolution in our understanding of the function of the
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AKAP complex. In chapter two, I demonstrated that AKAP7γ is able to bind to
itself, forming a dimer that has the potential to augment PKA phosphorylation.
This indicates that in addition to other complex components being present or not,
the stoichiometry of the AKAP complex is important and impacts the function of
the complex. In chapter 3, I showed that AKAP7γ binding to PLB is
phosphorylation-state dependent and that this state dependent mode of binding
allows small quantities of the AKAP complex to control phosphorylation of large
quantities of substrate. This work indicates that the AKAP complex is likely not a
static entity in which AKAP binds to the necessary signal components, recruits
them to a particular substrate, and remains in a stable complex. The AKAP
complex is more likely a dynamic structure that may change composition
continually due to binding and unbinding of components, or may change as a
result of certain signaling events as we see with the AKAP-PLB interaction.
Finally, in chapter 4, I added to the accumulating evidence that suggests the PKA
catalytic subunit does not dissociate from the AKAP complex to phosphorylate its
substrates. This work also demonstrates the importance of the structure or
topology of the AKAP complex. While I demonstrated that the structure of the
PKA regulatory subunit tether alters rates of phosphorylation, AKAPs themselves
are also flexible structures that may allow for positional variation in
phosphorylation rates of some AKAP complex components. Overall, this work is
an important step forward towards understanding how AKAP complexes function.
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In the following sections I present some final commentary on each of the
chapters and discuss the potential for future work.

AKAP7γ Oligomerization augments PKA signaling
This chapter represents my earliest work and deserves some reinterpretation in light of the results presented in chapter 4. While I remain
convinced of the ability of AKAP7γ to form dimers, and potentially higher order
oligomers that were undetectable by PCH, I no longer believe that release of the
catalytic subunit is necessary for PKA to phosphorylate its AKAP bound
substrates. The mechanism of the feed-forward loop that defines activation and
release of the catalytic subunit was partly a mechanism for dealing with the
reported high cellular concentration of cAMP (1µM) and very high affinity of the
regulatory subunit for cAMP. In my initial attempts to model the AKAP complex,
controlling the activation and release of PKA was problematic. This was primarily
due to the fact that the published kinetics defining activation and release led
either to very high baseline activity of PKA, or conversely, made it very difficult to
get an appropriate response to stimulation of β-adrenergic activity. Evidence
presented by Martin et al suggested that auto-phosphorylation of the regulatory
subunit was necessary for the release of catalytic, which provided us with a
potential way to deal with the problematic activation/release kinetics (51). With
the kinetics that required higher levels of cAMP for activation of PKA, requiring
auto-phosphorylation of the regulatory subunit for release of the catalytic subunit
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generated a feed-forward loop that gave an appropriate response to stimulation,
and also demonstrated that oligomerization of AKAP7γ could potentiate
increases in substrate phosphorylation. This hypothesis is still valid if one does
not accept the emerging evidence that the catalytic subunit is not released from
the AKAP complex in the cell.
Alternatively, if the catalytic subunit is not released from the oligomeric
AKAP complex, the accelerated kinetics

and increased magnitude of

phosphorylation would depend on the topology of the complex and accessibility
of each of the catalytic subunits to the complex bound substrate(s). Since PKA is
also known to alter the activity of other potential components of the complex
including AC, PDE, and PP1, the presence of multiple catalytic subunits in an
oligomeric complex could also impact phosphorylation via regulation of cAMP
production and degradation, or alteration in substrate dephosphorylation kinetics.
We did not find this to be the case with our current version of the AKAP7γ
oligomer model. However, a thorough investigation of the impact of
oligomerization for an AKAP complex in which the catalytic subunit is not
released would require construction of an entirely different model.
To continue this work, the effect of oligomerization of AKAP7γ on substrate
phosphorylation in live cells needs to be demonstrated. The most direct way to
assess this is to disrupt oligomerization in the cell and examine the levels of
substrate phosphorylation pre and post β-adrenergic stimulation. While this could
be done easily by generating a deletion mutant lacking the self-association sites,
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these sites overlap with regions that would impact binding of other AKAP
complex components, including PKA. Though difficult, it may also be possible to
design reagents that could disrupt oligomerization. Similar to the design of Ht31,
which dissociates PKA from AKAPs (19), short peptides mimicking the selfassociation sites may have a higher affinity for AKAP7γ than itself, resulting in the
disruption of oligomerization. Alternatively, the impact of having multiple PKA
molecules in the same complex could be assessed by creating a series of AKAR
sensors linked to varying numbers of PKA binding sites.
	
  
Phosphorylation-state

dependent

interaction

between

AKAP7δ/γ

and

phospholamban increases phospholamban phosphorylation
This work provides an answer to a long standing and important question in
the field of AKAP and cardiac biology: how does a protein like AKAP7γ, which is
present in the cell at low concentration, control phosphorylation of a high
concentration, widely dispersed protein like PLB or troponin. Additionally, this
work also revives the importance of the AKAP7γ-PLB interaction, which has not
been published on since 2012 when Jones et al suggested that it does not
regulate PLB phosphorylation (90). While the computational model presents
compelling data demonstrating that phosphorylation-state dependent binding of
AKAP7γ with PLB greatly increases the magnitude of phosphorylation by
AKAP7γ bound PKA, the next logical step for this work is to demonstrate this
phenomenon experimentally. The phosphorylation state dependence of AKAP7γ
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binding to PLB suggests that the complex should be highly mobile in response βadrenergic stimulation. This mobility should be demonstrable via fluorescence
resonance after photobleaching (FRAP). Comparison of the mobility of a GFP
tagged AKAP7γ could be made a series of cell systems containing either a nonphosphorylatable PLB (S16A), WT PLB or a phospho-mimetic PLB (S16D). In
this comparison, it would be expected that AKAP7γ has the lowest mobility in the
PLB(S16A) system, an intermediate mobility in the WT PLB system, and the
highest mobility in the PLB(S16D) system. This phenomenon could be further
explored by examining the mobility of AKAP7γ-GFP in rat neonatal cardiac
myocytes, which express endogenous PLB, pre and post β-adrenergic
stimulation.
The phosphorylation state dependence of AKAP7γ-PLB binding also
highlights the possibility that other AKAP binding partners also have state
dependencies. Though controversial, evidence does exist that the affinity of RIIα
for the PKA binding domains of AKAP7, mAKAP, and AKAP-Lbc is altered by
RIIα phosphorylation (107). Similar changes in affinity following phosphorylation
may exist for other AKAPs and their substrates, as well as for other binding
partners like AC, PDE, etc. Such findings would be a clear indication that AKAP
complexes are highly dynamic structures.
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Langevin Dynamic Simulation of AKAP-PKA Complex: Re-envisioning the local
concentration mechanism for directing PKA phosphorylation
The work presented in chapter 4 is certainly the most controversial, but
also has the most exciting implications. The ability of the AKAP-PKA complex to
retain the catalytic subunit following stimulation of cAMP production provides a
very clear molecular mechanism that explains not only how AKAPs are able to
compartmentalize cAMP-PKA signaling, but also indicates that the purpose of
AKAPs is likely to enhance the efficiency of phosphorylation specific PKA. As is
the case with most scientific progress, this work leads us to ask nearly as many
questions as it answers. If the catalytic subunit retains its activity while still bound
to the PKA regulatory subunit, how does PKA respond to increases in cAMP?
How can the catalytic subunit phosphorylate substrates if the regulatory subunit
is bound via the catalytic cleft? Are there specific conditions that determine
whether or not the catalytic subunit is released? Unfortunately many of these
questions are unlikely to be answered soon, and will need to wait for advances in
technology that have not yet occurred. The structure of the entire PKA complex
has yet to be solved due to the high degree of flexibility of the tether region. To
capture the conformational changes in the catalytic subunit during a signaling
event, within the AKAP complex, and in the cell would be an incredibly difficult
task.
The most important follow up on this work is to demonstrate in a live cell
whether or not the catalytic subunit is released in response to β-adrenergic
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stimulation. This can be accomplished via total internal reflectance fluorescencesingle particle tracking microscopy (TIRF-SPT). By tagging the catalytic subunit
with a photo-switchable fluorophore like mEOS, we can image the population of
mEOS-catalytic that is recruited to the cell membrane by AKAP and track the
number of catalytic subunits at the membrane over time, in the presence and
absence of β-adrenergic stimulation. I have conducted preliminary experiments
with AKAP79 demonstrating that these experiments are possible. Unfortunately,
AKAP79 does not stably associate with the membrane, making interpretation of
catalytic release extremely difficult. This work would be better conducted using
AKAP7α, which associates with the plasma membrane via post-translational lipid
modification that allows for insertion into the plasma membrane. AKAP7α should
form a stable association with the plasma membrane allowing for easier tracking
of mEOS-catalytic. AKAP7α also offers the additional advantage of not
associating with any signal components other than PKA and the ion channels
that are its target substrates, making interpretation of the data much easier.
Since our preliminary experiments seem to indicate that the catalytic subunit is
released in response to high concentrations (10µM) of the β-adrenergic agonist,
isoproterenol, and the direct activator of adenylate cyclase, forskolin, it is
important to explore the response of the catalytic subunit to lower, more
physiologically relevant drug concentrations.
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Concluding Remarks
Overall, this work offers a number of novel and important ideas regarding the
function of AKAP complexes. I have demonstrated the importance of both
stoichiometry and structure of AKAP complex components, and have shown that
AKAP complexes are likely to be more dynamic than previous thought. While this
work goes a long way towards answering some major questions in the field of
AKAP biology, it also provides avenues for important future work.
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